Politicians, athletes, journalists, NGOs, companies... They all use
corporation-owned social networks to communicate with us. Citizens
shouldn't have to hand over their data to companies to read content
published by public entities. Public Feeds changes that by making posts
of popular accounts freely available.
Read more.
International Vaccine Institute
The International Vaccine Institute (IVI) is a non-profit, autonomous international organization established with the mandate of making vaccines available to all. Collaborating closely with the global scientific community, public health entities, governments, and industry stakeholders, IVI focuses on vaccine research and deployment. This includes conducting new vaccine designs in laboratories, advancing vaccine development and assessment in real-world settings, and facilitating the sustainable integration of vaccines in regions where they are most urgently required. More on Wikipedia
Congratulations to Prof. Helen Rees, Chairperson of IVI’s Board of Trustees, on receiving the Global Achievement Award at the University of Cambridge Alumni Awards.
We are proud to have her guiding IVI into its next chapter as we launch our 2027–2031 Strategy.
Congratulations to our Executive Director, Professor Helen Rees, on being named the Global Achievement Awardee at the inaugural Cambridge Alumni Awards 2026.
A pleasure to welcome Ambassador @AmbSeanHoy of @IrishEmbKorea 🇮🇪 to IVI headquarters in Seoul. We discussed IVI’s work to discover, develop, and deliver safe, effective, and affordable vaccines, and look forward to building on this exchange and collaborating more closely.
It was a pleasure to welcome H.E. Fatou Gaye Ngom, Ambassador of Senegal to Korea, to @IVIHeadquarters. We discussed our growing partnership, including collaboration with Institut Pasteur de Dakar and efforts to advance vaccine research and biomanufacturing capacity in Africa.
IVI is proud to partner with @hkjcghi in bringing Africa and Asia together to build the research networks that make faster outbreak response possible.
The Hong Kong Jockey Club Global Health Institute@hkjcghi
🌏 Readiness starts before the next outbreak.
Today, around 90 experts and public health leaders from Africa and Asia are gathering to strengthen research networks and collaboration, helping research start faster and generate evidence when the next health emergency strikes.
IVI mourns the passing of Prof. Fred Newton Binka, a pioneering malaria researcher, educator, and former IVI Board of Trustees member (2014–2020), pictured here (center) with our director general and then-board chair.
Our heartfelt condolences to his family and colleagues.
Eliminating cervical cancer starts with prevention. On World Cervical Cancer Elimination Day, discover how IVI’s SHIELD project is exploring earlier HPV vaccination through routine childhood immunization to reach more children.
IVI’s 2027–2031 Strategy sets a course for advancing vaccine innovation, strengthening outbreak preparedness, and building sustainable regional vaccine capabilities.
Together with our partners, we’re turning science into impact.
IVI’s new 2027–2031 Strategy prioritizes vaccine innovation, outbreak preparedness, and stronger regional vaccine capabilities, with a focus on measurable public health impact.
Two days, 30+ talks, 29 posters: IVI’s 25th Scientific Advisory Group meeting reviewed our work, from Klebsiella and Strep A vaccines to MERS readiness.
Thank you to the group’s members and to outgoing Chair Prof. Fred Zepp for his years of guidance.
Where vaccines are made matters. Expanding regional manufacturing could strengthen resilience, scientific capacity, and health security while helping address inequities in vaccine access.
Seed funding from Coefficient Giving will help IVI establish the BRIGHT Fund to accelerate collaborative global health innovation and expand equitable access to life-saving technologies.
More photographs that stayed with our Grand Jury. 📷
Meet the Honorable Mentions of the IVI 4th International Photo Contest—more perspectives on health, vaccination, care, and communities around the world.
At the Global Training Hub for Biomanufacturing, participants explored biosafety risk assessment, protective equipment, biological material handling, and waste management to help protect people and vaccine quality.
IVI welcomed a delegation from Lithuania’s embassy and life sciences-biotech sector to Seoul for discussions on vaccine R&D, emerging technologies, and pandemic preparedness.
Thank you for the engaging exchange and shared interest in advancing vaccine innovation.
How can vaccine technology be transferred swiftly during a pandemic?
At the Global Training Hub for Biomanufacturing, participants explored how planning, technical readiness, and knowledge sharing can speed vaccine production in a hypothetical scenario.
IVI welcomed H.E. Paul Sobba Massaquoi, Ambassador of Sierra Leone to Korea, to its Seoul HQ. Director General @drjeromekim1 and the Ambassador reviewed IVI’s work in Sierra Leone and explored ways to expand in the years ahead.
Who owns vaccine technology—and who gets to use it?
At the Global Training Hub for Biomanufacturing, participants are exploring how licensing agreements can protect innovation, clarify manufacturing rights, and support affordable vaccine access.
A vaccine cannot save lives if people cannot access it. Scientific progress must be matched by manufacturing, financing, health systems and public trust.
Vaccine innovation is also about delivery: combination vaccines, fewer repeat visits and microarray patches could make vaccination simpler and more accessible.
Challenges of delivering cholera vaccines vary across countries, but lessons can be shared.
At IVI's workshop in Seoul, experts from Ethiopia, Mozambique, and Zambia exchanged experiences and explored ways to improve vaccine access and delivery.
mRNA vaccines gained global attention during COVID-19, but the technology had been developing for years. This SciPod audio feature looks at why mRNA could matter for future outbreaks and vaccine development.
Today, we join researchers, governments and partners for the launch of this important initiative. Representing the @WHOAFRO Regional Director, Dr @BrakaFiona is sharing @WHO’s commitment to the partnership to strengthen research preparedness and collaboration across the region.
MRC Unit The Gambia in partnership with @IVIHeadquarters is proud to share the launch of the Africa #researchpreparedness Programme in West Africa, an important milestone towards operationalising the Hub and Spokes Network in the region.
Primary focus: create a pathway to rapidly activate and coordinate clinical studies during #publichealth emergencies, and a coordinated and community-centred #clinicalresearch ecosystem.
Together with @AfricaCDC and @CEPIvaccines, the launch brought together government representatives, regional institutions, including the @AU_AMA_ and @WHO Regional Office for Africa, participating research institutions, national public health institutes, national ethics committees, funders and partners.
Over two days, the launch and stakeholder sessions will provide an opportunity to build a shared understanding of the programme, align priorities and identify the next steps towards operationalising the Hub and Spokes Network.
Discussions will focus on strengthening coordination, clarifying roles and responsibilities, and connecting existing capacities to support a more coordinated and responsive clinical research ecosystem across #westafrica.
The 2026 Introductory Course for Standard Practice (GxP) is underway in Korea, bringing together 155 professionals from 30 countries to strengthen vaccine and biologics manufacturing skills.
In Accra, IVI joined @AfricaCDC, @CEPIvaccines, and regional research institutions to shape how the Hub-and-Spoke Network will operate, strengthening collaboration and research readiness for future outbreaks across West Africa.
Oral cholera vaccines save lives. Timely delivery could save more.
An IVI-led study in npj Vaccines estimates that global stockpile-supported campaigns averted 8.1 million cholera cases and 146,000 deaths from 2013–2025.
Vaccination in older adults is about more than preventing infection. Researchers are also exploring whether some vaccines may contribute to healthier aging. Hear the full SciPod audio feature.
Advancing adult immunization policy alignment in the Asia-Pacific!
On the sidelines of the World Bio Summit in Seoul, IVI brought together policymakers and experts from nine economies to identify shared priorities and strengthen regional cooperation.
IVI was honored to welcome Tunisia’s Minister of Health, H.E. Prof. Mustapha Ferjani, and Ambassador to Korea, H.E. Kais Darraji, to IVI headquarters in Seoul to discuss strengthening cooperation in vaccine development, biomanufacturing, and capacity building.
Today, we join researchers, governments and partners for the launch of this important initiative. Representing the @WHOAFRO Regional Director, Dr @BrakaFiona is sharing @WHO’s commitment to the partnership to strengthen research preparedness and collaboration across the region.
How can vaccination during pregnancy help protect newborns? It can generate antibodies that are transferred before birth, helping protect infants during their first vulnerable months.
How can we better understand what shapes public trust in science?
IVI Director General @drjeromekim1 joins Dr. Cary Funk on the @wellcometrust podcast to explore findings from the Wellcome Global Monitor and why listening to communities matters.
Could early signs of heart damage help advance Strep A vaccine development?
A new paper from IVI and collaborators explores whether early rheumatic heart disease, detected by heart ultrasound, could help researchers evaluate future vaccines.
Only a few days to go until our webinar: Africa-Nordics Pharmaceutical Partnerships: A New Innovation Corridor.
Join leading voices from IVI-Europe, Bio Usawa, Rwanda Biomedical Center, Bayer and KEMSA for a moderated conversation on innovation, clinical research and market access.
📅 15 October 2026 🕒 15:00-16:30 CEST 💻 Online, with live Q&A
Registration closes on 13 October at midnight (CEST). If you would like to join us, please register here: forms.gle/ohixuKLYjyHeLTZs6
Today, RBC, in collaboration with partners, concluded a 5-day workshop on #clinicaltrial management for researchers and healthcare professionals from clinical trial units at five health facilities: @RwaMilitaryHosp, @chu_butare , @kfaisalhospital , and @ughe_org -AVEGA. The training strengthens local capacity to conduct high-quality clinical trials, generate reliable evidence, and support better health outcomes.
This is an important step toward building these facilities into Centers of Excellence for Clinical Trials in the region. By strengthening research skills and infrastructure, #rwanda is advancing its ambition to become a destination of choice for cutting-edge #medicalresearch, while building a stronger, sustainable clinical research ecosystem that benefits Rwanda and beyond.
Colleagues across our global offices celebrated IVI Foundation Day this week with games in Asia, cultural festivities in Africa, and team activities in Europe.
Different cultures, diverse talents, one shared mission: vaccines for global health.
As the ongoing Ebola BDBV outbreak highlights the need for outbreak-ready systems, IVI is co-organizing a special workshop at #isv2026 on vaccine R&D, manufacturing, and preparedness.
IVI and Leyden Labs have established a new partnership to explore collaboration on mucosal protection platform development, bringing together expertise and capabilities across Korea, Singapore & the Netherlands to advance new approaches to infectious disease prevention.
Delighted to meet with Professor Nicaise Ndembi, Deputy Director General of the International Vaccine Institute.
The UK is a proud partner of IVI’s work to deliver effective vaccines for infectious diseases, & to unlock the potential for African manufacture of vaccines. 🇬🇧🤝🌍
International Vaccine Institute (IVI) reposted
Embassy of the Republic of Korea in Rwanda@korea_rwanda
Ambassador HUH Jungae Met with International Vaccine Institute (IVI) Africa Regional Office (Sep 4, 2026)
On September 4, 2026, Ambassador HUH held a meeting with Nicaise Ndembi, Deputy Director of the International Vaccine Institute (IVI) Africa Regional Office.
Today, I had the pleasure of hosting Professor Nicaise Ndembi PhD, MPH, Deputy Director General and Regional Director, International Vaccine Institute (IVI) Africa Regional Office with his team at the Chancery.
The Hong Kong Jockey Club Global Health Institute@hkjcghi
🌍 We're live! Together with @WHOSEARO and @IVIHeadquarters, we invite you to join our side event at the 79th Session of the WHO Regional Committee for South-East Asia.
All Projects Review: an annual showcase of research underway across IVI.
Through 60 presentations, researchers shared their work and exchanged questions and feedback, with selected projects advancing to our Scientific Advisory Group for further expert review.
After six years, IVI’s cholera control project in Mozambique concludes with 200,000 vaccine doses administered, stronger surveillance, and support for the National Cholera Plan.
Each year, IVI supports promising vaccine professionals from low- and middle-income countries to join the International Vaccinology Course, share research, and build global connections.
At Careers in Vaccinology panels in Seoul, Kigali, and Stockholm, scientists and senior professionals shared career lessons, challenges, and opportunities with International Vaccinology Course participants.
IVI and Sweden’s @karolinskainst have signed an MoU to strengthen existing cooperation in vaccine research and education—and expand initiatives that translate innovation into better health outcomes worldwide.
IVI is pleased to support 11 health professionals with government-funded scholarships to participate in #ivc2026.
With support from India, Thailand, and the Philippines, these scholarships strengthen expertise, knowledge exchange, and vaccine capacity where it matters most.
“Vaccines for a Connected World: A One Health Perspective” 🌍
Across Seoul, Kigali, and Stockholm, this year’s International Vaccinology Course explores how human, animal, and environmental health shape vaccinology, outbreak preparedness, and public health.
A safe and effective vaccine is only part of the challenge.
At the International Vaccinology Course, participants in Seoul, Kigali, and Stockholm are exploring vaccine hesitancy, barriers to uptake, and how communication can build trust in vaccination.
IVI was proud to commemorate Malaysia’s accession to IVI at NICE 2026 in Kuala Lumpur. We look forward to deepening cooperation with Malaysia on vaccine research, development, innovation, and capacity strengthening.
IVI welcomes the opportunity to strengthen collaboration with Italy and the Fondazione Biotecnopolo di Siena in vaccine innovation, biotechnology, and pandemic preparedness.
Good discussions in Seoul on advancing cooperation among Italy, IVI, and Korea in vaccine innovation and global health.
At the Italian Embassy, I met Amb. Emilia Gatto and Prof. Rino Rappuoli of Fondazione Biotecnopolo di Siena, who later spoke at @IVIheadquarters on AMR.
What does GMP look like in practice? Gain hands-on experience applying GMP principles and MFDS regulatory requirements in a real biomanufacturing setting.
🇬🇧 During her visit to CISM on 14 August, Se Eun Park, from the @IVIHeadquarters, highlighted the CISM’s scientific capacity and the potential for future collaborations in vaccine research and development and capacity strengthening. #cism30#globalhealth youtu.be/HD-15aU62eU
From Bach and Mozart to Elgar, music took center stage at the 24th Lee Sang Hee & Friends Concert with IVI in Seoul.
The benefit concert also marked a milestone: KRW 1 billion in cumulative donations supporting IVI and other meaningful causes. Thanks to all who made it possible.
Congratulations and thanks to violinist Lee Sang Hee & Friends on their 24th annual benefit concert and reaching KRW 1 billion in donations benefiting IVI and other causes.
For 20+ years, they’ve shown how music can inspire generosity and advance global health through vaccines.
IVI welcomed the 2026 Dr. Lee Jong-wook Fellowship cohort to our headquarters in Seoul.
Through exchanges on clinical development, epidemiology, and vaccine delivery, health professionals from 10 countries across Africa and Asia are building connections to advance global health.
IVI was honored to visit the Embassy of Sierra Leone in Seoul and meet with Dr. Paul Sobba Massaquoi, Ambassador of Sierra Leone to the Republic of Korea.
We discussed strengthening collaboration in vaccine R&D and public health. Looking forward to our continued partnership.
In Chandigarh, India, IVI visited a research site tracking Strep A infections and met affected families. The data collected can help researchers develop and test future vaccines.
IVI remembers Prof. Wan Kyoo Cho (1928–2026), a distinguished biologist, educator, and public servant, and one of the institute’s founders who was a lifelong champion of science, global health, and international cooperation.
IVI welcomed Director-General Jae-hwan Kwon of @MOFAkr_eng for a seminar on ASEAN cooperation, vaccine ecosystem development, and regional health security. We thank him for sharing insights on strengthening regional partnerships.
A pleasure to welcome Ambassador Eva Marie Russek of Austria to IVI headquarters.
Director General @drjeromekim1 and Ambassador Russek discussed IVI’s latest vaccine innovations, global health priorities, and our mission to make life-saving vaccines affordable and accessible. 🇦🇹
mRNA technology has immense potential for vaccine development, and COVID-19 progress was only the beginning.
At the recent mRNA symposium in Stockholm, @drjeromekim1 highlighted lessons learned from the pandemic and how the gains made must be sustained for global health impact.
At the @ASEAN Meeting on Vaccine Security and Self-Reliance (AVSSR) in Bangkok, I joined colleagues from @NVITH_Official@WorldBankGroup@RVMCollab to discuss how partnerships across R&D, manufacturing, financing, and regulation can help strengthen vaccine security in ASEAN.
We were pleased to welcome Dr. Oliver Morgan of the WHO Pandemic Hub to IVI for discussions on innovation, data-driven approaches, and global health security.
Pandemic preparedness depends on strong partnerships, scientific collaboration, and turning innovation into action.
Thank you to Prof. Ivan Hung for the warm welcome and tour of @hkumed. It was a pleasure to review progress on @IVIHeadquarters contributions to the Hong Kong Jockey Club Global Health Institute and discuss new opportunities for joint clinical/effectiveness research.
Thank you to Dr. Fumihiko Yasui and Dr. Bum Sik Chin for joining the IVI–Japan Engagement Seminar to share insights on mpox research and vaccine development.
This exchange of expertise between Korea and Japan was made possible by the Korea Support Committee for IVI.
IVI was pleased to welcome H.E. @kojochoi, Ambassador of the Republic of Ghana to the Republic of Korea, to our headquarters.
Building on nearly two decades of collaboration, discussions explored opportunities to strengthen vaccine R&D and access, technical capacity, and more.
🌍 Intellectual Property, Technology Transfer, and Sustainable Financing for Vaccine Access: Building a Global South-Led Innovation Ecosystem in Africa 🗓 18 June 🕙 10:00 a.m.–12:00 p.m. 📍 Cairo
IVI was pleased to welcome Vice Minister Angélica Arias Benavides and Ambassador Patricio Esteban Troya Suarez of Ecuador to our headquarters in Seoul. 🇪🇨
We look forward to continued collaboration to strengthen global health.
Another milestone in the collaboration between the @Uni_Rwanda and leading international institutions on impactful health research such as Institut Pasteur and @IVIHeadquarters. Today marks the kick-off of the Accelerating Clinical Trial for CHIKungunya vaccine in Africa (ACT-CHIK) Consortium, a 4-year EU-funded (€15.3M) clinical trial project on Chikungunya vaccines, bringing together partners from Rwanda, Kenya, Nigeria, Senegal, Brazil, South Korea, and France. The project aims to strengthen Africa’s clinical trial capacity, advance vaccine research, and explore pathways for local vaccine manufacturing on the continent.
We are delighted to welcome Prof. Helen Rees as Chairperson of the IVI Board of Trustees.
A globally respected physician, researcher, and public health leader, Prof. Rees brings decades of experience advancing vaccine access, epidemic preparedness, and health equity worldwide.
Rwanda Biomedical Centre, in collaboration with @IVIHeadquarters and @expertisefrance through the MAV+ Initiative, hosted the Dissemination Meeting on the Clinical Trials Quality Management System (QMS) Gap Assessment Findings.
As part of ongoing efforts to strengthen #rwanda’s clinical trials ecosystem and enhance institutional readiness for high-quality clinical research, a QMS gap assessment was conducted by RBC and IVI across five selected health facilities.
At the event, DG @CMuvunyi emphasized that the dissemination of these findings represents an important milestone in advancing the health sector’s vision of positioning Rwanda as a competitive and trusted destination for high-quality #clinicalresearch.
He noted that the findings will help inform the next steps toward strengthening clinical research systems and capacities nationwide.
We were honored to welcome Rt. Hon. Helen Clark, Chair of the Board of @gavi, to IVI headquarters in Seoul.
She and @drjeromekim discussed the future of global immunization, vaccine equity, and the importance of sustained investment in solutions for persistent disease threats
New research in @NatureMedicine explores how advances in vaccine science—from mRNA platforms to life-course vaccination—could shape the future vaccine landscape.
Jerome Kim & Nicaise Ndembi review the global #vaccine development landscape, focusing on expanding target populations, emerging technologies, and cross-cutting issues such as societal value, funding & access, and regional manufacturing @IVIHeadquarters dlvr.it/TSfk0R
At an official #wha79 side event hosted by @DOHgovph, IVI, and partners, global leaders advanced the conversation on vaccine self-reliance, regional manufacturing, and stronger pandemic preparedness.
At our #wha79 event, global health leaders called for stronger clinical trials systems to advance health equity and preparedness through trusted partnerships and locally driven research.
To know George Bickerstaff is to hear these words often—not simply as a saying, but as principles he has lived by throughout 17 years of service to IVI.
As George steps down from the Board of Trustees, we thank him for his visionary leadership.
Held talks with International Vaccine Institute (IVI) Director-General Jerome Kim at State House Nairobi. We have had a strong partnership with the IVI for over 20 years. This relationship has blossomed and recently culminated in the election of our country to the vice-presidency of the IVI Global Council and consequently to the Board of Trustees.
We are committed to continued collaboration in vaccine research and development, clinical trials, manufacturing partnerships, strengthening regulation, and staff development.
Additionally, IVI will be working closely with our academic and research institutions, including the Kenya Medical Research Institute, Kenya Biovax Institute, Pharmacy and Poisons Board.
At #interest2026, IVI’s symposium on “Building Africa’s Vaccine R&D and Manufacturing Ecosystem” highlighted the importance of African-led innovation, partnerships, and manufacturing capacity to advance vaccine sovereignty and achieve the AU goal of 60% local vaccine production.
The future of global health depends on stronger regional manufacturing, equitable partnerships, and African-led innovation.
IVI @drjeromekim1 was proud to join the #africaforward Summit in Nairobi to advance collaboration on vaccines and resilient health systems across Africa.
Vaccine equity and pandemic preparedness require a shift to local biomanufacturing.
Join IVI, @DOHgovph, and partner countries at #wha79: “Advancing Biomanufacturing Self-Reliance” 🕕 20 May 2026 18:00–19:30 📍 Palais des Nations, Geneva
Turning ambition into action: IVI and partners convened in Manila to advance vaccine self-reliance—focusing on R&D, manufacturing, financing, and partnerships for sustainable health systems.
In Manila for IVI’s Global Council meeting, we visited the Research Institute for Tropical Medicine and NIH labs to learn about the Philippines’ strengths in public health research.
“On the other side of the world, my country is experiencing the same challenge,” a member shared.
Join us at INTEREST 2026 for a symposium: Building Africa’s End-to-End Vaccine R&D and Manufacturing Ecosystem: ACHIEVE Africa’s Vision, Progress, and Roadmap to Sovereignty 🗓 12 May 🕓 4:15–5:00 PM 📍 Dar es Salaam, Tanzania
IVI’s Global Council met in Manila to guide long-term strategy and governance, including the election of new leadership and representatives, under @DOHgovph leadership.
At an important time in global health, IVI’s Global Council convenes in Manila to guide IVI’s priorities in vaccine equity, governance, and regional capacity.
Kenya was elected Vice-President, with Brazil and Kenya elected to the IVI Board of Trustees.
Global health is under pressure—but change is underway.
Hear @drjeromekim1 and Dr. Anh Wartel on Cytiva’s Discovery Matters podcast discuss funding shifts, rising regional leadership, and what it means for pandemic preparedness.
“Growing up, the BCG scar on my arm became something everyone recognized and talked about, reflecting how the burden of tuberculosis shaped our generation.”
At IVI, vaccines are our work, and they are also personal. We are scientists and advocates while also being siblings, parents, and neighbors who see their impact every day.
IVI was honored to host a Kenyan delegation representing KEMRI, Embassy of Kenya to the Republic of Korea, Commission for University Education, and other institutions to exchange knowledge and explore partnerships.
Advancing vaccine equity across Kenya, Africa, and beyond.
“Vaccines don’t save lives—vaccinations save lives.” — Prof. Walter A. Orenstein
At the 2026 IVI–SK bioscience Park MahnHoon Award in Seoul, we honored: • Prof. Walter A. Orenstein • Developing Countries Vaccine Manufacturers Network
John Clemens & Jan Holmgren received the 2026 John Dirks Canada Gairdner Global Health Award for transforming how we prevent & control cholera by developing safe, effective & affordable oral vaccines.
Congratulations to Prof. Nicaise Ndembi and Prof. Helen Rees on being named to Africa Health 20 by @ReadMeridian—recognizing leaders shaping Africa’s health agenda.
Proud to work alongside them in advancing IVI’s mission.
Vaccine equity and pandemic preparedness require a shift to local biomanufacturing.
Join IVI, @DOHgovph, and partner countries at #wha79: “Advancing Biomanufacturing Self-Reliance” 🕕 20 May 2026 18:00–19:30 📍 Palais des Nations, Geneva
IVI and Dhulikhel Hospital, Kathmandu University Hospital have established an IVI Collaborating Center in Nepal 🇳🇵
Building on a partnership since 2018, the center will advance research, capacity building, and work on infectious diseases, vaccines, and pandemic preparedness.
Join us during WHA79 in May for a high-level dialogue on strengthening clinical trial systems.
IVI, the Pasteur Network, and co-hosting countries will bring stakeholders together to drive collaboration and advance equitable global health research.
We applaud Deputy Director General/Regional Director Prof. Nicaise Ndembi (@Ndembi12) on being named to the Africa Health 20 (2025) by @ReadMeridian—highlighting leaders shaping the continent’s health future.
Prof. Nicaise Ndembi Honoured to moderate this key session at #ahas2026 Session Title: Vaccine and related products ,Equity & Pandemic Preparedness 🕒 10:00 AM – 11:00 AM GMT 📍 Serena Hotel, Kigali Secure your ticket 👉 zenithglobalhealth.com/ahas-africa-ticket/
IVI’s collaboration with Zambia continues to deepen 🇿🇲
Engagements with @ZambiaMFAIC Etambuyu Anamela Gundersen and @ZMPublicHealth Roma Chilengi highlight shared commitment to advancing vaccine R&D, strengthening partnerships, and building a resilient ecosystem across Africa.
IVI’s partnership with Zambia is advancing vaccine R&D and health security.
Dr. Douglas Shaffer met with @mohzambia Minister of Health Dr. Alex Katakwe to explore new opportunities—building on the momentum of ACHIEVE Africa and strengthening African-led vaccine ecosystems.
We’re proud to see Deputy Director General/Regional Director Prof. Nicaise Ndembi (@Ndembi12) featured among @EDCTP3’s researchers shaping the future of global health.
His leadership continues to strengthen global health systems.
On YoGlo Talks—a podcast by youth, for youth—a young global health advocate speaks with Dr. @drjeromekim1 on vaccine equity, global collaboration, and the role of the next generation in shaping global health.
Bringing partners together to enhance vaccine access and last-mile delivery in Zambia.
IVI's @DrSeEunPark and partners @mohzambia convened a stakeholder workshop in Lusaka to review results on a controlled temperature chain strategy for oral cholera vaccines.
Center for Emerging Pathogens and One Health@CEPOH_Rwanda
Webinar on vaccinology: Pandemic Preparedness and Vaccine Discovery and Development in Africa. with Prof. Nicaise Ndembi, DDG, Regional Director and Head of Mission at @IVIHeadquarters , Africa Regional Office #rwanda
Um novo modelo de inovação em saúde no Sul Global está tomando forma.
O IVI e o Brasil assinaram cartas de intenção em apoio ao Fundo BRIGHT, criado para acelerar o desenvolvimento, a produção e o acesso a tecnologias que salvam vidas.
A new model for health innovation in the Global South is taking shape.
IVI and Brazil have signed letters of intent supporting the BRIGHT Fund—designed to accelerate development, manufacturing, and access to life-saving technologies.
Instituto de Salud Carlos III (ISCIII)@SaludISCIII
Hemos recibido la visita en el #isciii de una delegación del International Vaccine Institute @IVIHeadquarters. Hemos mantenido una reunión para compartir objetivos comunes y recorrido algunas instalaciones y laboratorios de nuestro Centro Nacional de Microbiología.
A new model for health innovation in the Global South is taking shape.
IVI and Brazil have signed letters of intent supporting the BRIGHT Fund—designed to accelerate development, manufacturing, and access to life-saving technologies.
Director General Dr. Jerome Kim (@drjeromekim1) met with First Lady Kim Hea Kyung of Korea, the Honorary President of the Korea Support Committee for IVI.
They share a commitment to global health and vaccine equity.
Advancing collaboration on vaccine access, pandemic preparedness, and shared global health priorities, Dr. Douglas Shaffer, IVI Deputy Director General, met with Jeffrey Valdez of the Philippines’ UN Mission in Geneva.
We thank the Philippines for its global health leadership.
IVI’s presence in Austria and Sweden are European gateways for collaboration.
In Vienna, Dr. Jerome Kim met with representatives from Austria’s health and science ministries. Thanks to Dr. Katharina Reich and Barbara Weitgruber for the exchange on advancing vaccine development.
Advancing vaccines takes a meeting of minds. During Dr. Jerome Kim's @drjeromekim1 visit to our Stockholm office, we welcomed Pfizer’s Katherina Zakikhany-Gilg, Ralf René Reinert, and Andreas Palmborg to exchange insights on vaccine portfolios, priorities, and future innovation.
IVI is proud of our close connection with Sweden’s Karolinska Institutet.
IVI’s Dr. Jerome Kim @drjeromekim1 and Dr. Anh Wartel @t_wartel met with Vice President Martin Bergö to explore opportunities to further strengthen knowledge exchange and advance vaccine research.
Visiting Stockholm, Dr. Jerome Kim @drjeromekim1 met with State Secretary Karin Juhlin, to discuss how continued collaboration with Sweden can advance vaccine innovation, strengthen global health security, and expand equitable access to life-saving vaccines.
Behind every global health study is lab work—and people like Nigus Telele. As GLOBE-HPV lab coordinator, he helps harmonize procedures across eight countries and 29,500 participants, generating data to guide cervical cancer prevention and vaccination. 🔗: www.ivi.int/building-the-evidence-for-smarter-hpv-prevent…
On the sidelines of the 39th #ausummit, Member States launched Achieve Africa, a bold initiative to accelerate development of safe, effective vaccines and biologics. Sweden is proud to support through long-standing partnerships with IVI, Africa CDC, WHO AFRO, AHRI & others.
In Seoul, Minister of Health Alexandre Padilha, Anvisa, Fiocruz, and Ambassador Márcia Donner Abreu joined discussions on advancing global health innovation. 🌍
In Vaccines Beat, IVI's Nicaise Ndembi (@Ndembi12) highlights ACHIEVE Africa—connecting R&D, clinical trials, and manufacturing to deliver vaccines made in Africa, for Africa.
New research highlights the urgency—and momentum—behind vaccines for invasive non-typhoidal Salmonella (iNTS), a deadly but overlooked threat in low- and middle-income countries.
In Addis Ababa I gathered with key investigator and manufacturer partners of ACHIEVE Africa. Together, we are entering the next stage in the initiative’s journey, translating the initiative’s strategic intent into actionable steps.
Africa represents 17% of the world’s population but only 0.1% of global vaccine production, while accounting for about a quarter of global demand. The AU’s commitment to produce 60% of vaccines used on the continent by 2040 is therefore both strategic and necessary.
This ambition requires more than manufacturing. It demands an end-to-end ecosystem built on strong regulatory systems, African led R&D and sustainable financing.
@WHO stands ready to provide institutional and technical support, working with partners to ensure vaccines for Africa are developed, tested and produced on the continent to the highest standards of quality and safety.
Today, Minister of State @YvanButera joined an AU Summit side event marking the launch of ACHIEVE Africa, an International Vaccine Institute-linked initiative bringing together African and global partners to accelerate vaccines and therapeutics research & development on the continent — building end-to-end capacity from discovery to delivery.
“No continent should be left behind. Investment in research and development for the production of vaccines and medicines is critical to safeguarding lives,” said H.E. Hakainde Hichilema, President of Zambia.
Africa’s vaccine sovereignty is moving from ambition to action.
In @PremiumTimesng, Chinedu Moghalu and IVI's Nicaise Ndembi argue lasting resilience requires more than facilities—it demands strong R&D, regulation, financing, and talent.
A vaccination drive in Valenzuela, Philippines is telling a big story: every jab helps prevent infections, cut antibiotic use, and push back against antimicrobial resistance—a silent crisis disproportionally hitting low- and middle-income countries.
IVI is proud to join @CEPIvaccines and Korea’s @TheMFDS and @KoreaDCA in a first-of-its-kind pandemic simulation to strengthen vaccine readiness, regulation, and response at speed.
Join African leaders and partners for the launch of ACHIEVE Africa, a continent-led initiative powering Africa’s research and development engine, on the sidelines of AU39.
Grateful for the time and insights of Hon. Secretary Teodoro Herbosa (@DOHgovph), @RITMPH, and @WHOWPRO, IVI, led by Dr. Douglas Shaffer, met in Manila to strengthen IVI-Philippines collaboration on vaccine discovery, development, and delivery.
Under the Team Europe Initiative on Manufacturing and Access to #vaccines , Medicines and Health Technologies in #africa (MAV+ Project), RBC hosted @IVIHeadquarters , @expertisefrance & partners for high-level discussions on strengthening clinical trials readiness and establishing a national biobank in #rwanda.
The meeting marks a key step toward coordinated, sustainable strengthening of Rwanda’s #clinicaltrial ecosystem, anchored in national leadership and collaboration.
Honored to have met with @Dr_JeanKaseya, Director General of the @AfricaCDC, and his team. I share Africa CDC’s emphasis on partnership, co-creation, and political support to advance sustainable, continent-driven solutions, and I look forward to continued engagement.
I met today with Jerome Kim, Director General of the @International Vaccine Institute (IVI) (@IVIHeadquarters), at @AfricaCDC, together with our respecive teams, to advance collaboration on vaccine development, manufacturing, and clinical research in Africa.
Partnerships like this are essential to strengthening Africa’s vaccine ecosystem, accelerating innovation, and improving preparedness for future health threats. ------- J’ai rencontré aujourd’hui Jerome Kim, Directeur général de l’International Vaccine Institute (IVI), au Africa CDC, aux côtés de nos équipes respectives, afin de faire progresser la collaboration en matière de développement de vaccins, de fabrication et de recherche clinique en Afrique.
Des partenariats de ce type sont essentiels pour renforcer l’écosystème vaccinal africain, accélérer l’innovation et améliorer la préparation face aux futures menaces sanitaires.
“The growing importance of locally produced vaccines for locally relevant infectious diseases is exemplified by Biovac’s oral cholera vaccine entering a clinical trial – a first for end-to-end cholera vaccine production in Africa" - Dr Jerome H. Kim, @IVIHeadquarters.
International Vaccine Institute (IVI) reposted
The Hong Kong Jockey Club Global Health Institute@hkjcghi
HKJCGHI is proud to announce its membership in the Global Sustainable Preparedness Support Network (GSPN), a World Health Organization (WHO)-led initiative dedicated to strengthening global health emergency preparedness and resilience. Details: www.hkjcghi.org/ghi-who-gspn
“In 2026, vaccines, technologies, and stronger ecosystems are converging to expand access to vaccination and drive a more self-sufficient, resilient vaccine landscape.”
IVI wishes our global community a peaceful and healthy holiday season.
As we reflect on the past year, we’re deeply grateful for the partnerships and shared commitment that bring us closer to a healthier world made possible by vaccination, available to everyone, everywhere.
📣 We've launched a new $16m project with leading scientific organisations in Korea to advance the first-ever vaccine to protect against a potentially deadly tick-borne disease in Asia.
IVI, @CEPIvaccines, and partners are advancing the world’s first clinical development of an mRNA vaccine against SFTS, a growing tick-borne threat in Asia.
Strengthening regulatory systems is vital for global health.
IVI’s Train-the-Trainers Fellowship brought East African alumni to Korea for immersive training in regulatory science, good practices, and biomanufacturing—building skills, networks, and momentum for stronger systems.
IVI and the Regionalized Vaccine Manufacturing Collaborative (RVMC), hosted by @CEPIvaccines, signed an MOU in Oslo to deepen cooperation in strengthening the resilience and sustainability of vaccine manufacturing and supply chains: www.ivi.int/ivi-and-the-regionalized-vaccine-manufacturin…
We are grateful for the opportunity to meet and deepen collaboration with the @_AfricanUnion as we work together to advance vaccine production, health security, and a resilient, self-reliant Africa.
Pleased to meet today in Addis Ababa Dr. Nicaise Ndembi @Ndembi12, Deputy Director General and Regional Director of the International Vaccine Institute (IVI) Africa Regional Office @IVIHeadquarters. Appreciated IVI’s partnership in advancing Africa’s public health priorities and reaffirmed the AU’s commitment to strengthening vaccine production and health security as part of building a resilient and self-reliant #africa in line with Agenda 2063.
We are grateful to all who joined the IVI-@Uni_Rwanda Joint Symposium in Kigali, where researchers, clinicians, and the IVI Board came together—driving progress on innovation, vaccine science, and sustainable health systems across Africa.
IVI’s Board of Trustees met in Kigali this week for a reflective and forward-looking discussion on strengthening vaccine science and innovation across Africa.
Grateful to our partners in Rwanda for their collaboration and hospitality.
IVI and @NVITH_Official have renewed our long-standing partnership, strengthening vaccine R&D, international collaboration, and regional capacity building.
Together, we’ll continue driving progress toward stronger vaccine equity and preparedness across ASEAN and beyond.
The Kenya Bio-Vaccine Mission Program in the Republic of Korea (23rd–30th October 2025) brought together Kenyan experts and institutions, including @BioVaxInstitute, to benchmark @KOREA's world-class vaccine research, manufacturing, and innovation ecosystem. Through visits to @Celltrioninc , the International Vaccine Institute (@IVIHeadquarters ), Korea Advanced Institute of Science and Technology- KAIST (@kaistpr), the Public Contract Development and Manufacturing Organization (PCMO), and the Korea Disease Control and Prevention Agency- KDCA (@KoreaDCA) , the delegation explored opportunities in technology transfer, workforce training, and collaborative research to advance Kenya’s Smart Vaccine Manufacturing Facility (to be built at @konzatech). The mission strengthened bilateral partnerships, reaffirmed IVI’s commitment to supporting BioVax’s vaccine production agenda, and positioned the Institute as a key driver of Kenya’s journey toward vaccine self-reliance and sustainable health innovation. 🇰🇪🤝🇰🇷 #biovax#vaccinemanufacturing#kenyakoreapartnership#healthinnovation#smartvaccinefacility#technologytransfer#localproduction#africacdc#konzatechnopolis
International Vaccine Institute (IVI) reposted
The Hong Kong Jockey Club Global Health Institute@hkjcghi
On Nov 10, @hkjcghi & @IVIHeadquarters hosted a symposium in Bangkok on pandemic preparedness—sharing lessons from COVID-19 and strategies for rapid research during emergencies. Key message: “No country is safe until all countries are safe.” #globalhealth#pandemicpreparedness
Vaccine equity happens when global collaboration meets local empowerment.
@drjeromekim1 joins @AtMIndex The Health Equity podcast to discuss advancing vaccine security and incentivizing innovation for low- and middle-income countries.
On Thursday, October 30, 2025, in a strategic move to strengthen collaboration in vaccine research and development across Africa, @aphrc and the @IVIHeadquarters signed a Memorandum of Understanding (MoU) at the APHRC Campus in Nairobi.
This partnership establishes a strategic framework for joint efforts in vaccine research to discover, develop, and deliver vaccines in Africa; policy engagement and communication; strengthening the clinical trial ecosystem; capacity development; and resource mobilization. The two organizations will focus on tackling infectious diseases that disproportionately affect low- and middle-income countries.
Welcomed leaders from Hilleman Labs—jointly funded by Merck (MSD) and Wellcome—to explore #collaboration on affordable #vaccines for LMIC with KDCA, RIGHT Foundation & Adjuvant Capital. Insightful presentations + dialogue on funding gaps = powerful momentum for #globalhealth.
IVI, @CEPIvaccines, and Novo Nordisk Foundation Initiative for Vaccines and Immunity will host a conference 2–3 Dec in Stockholm to strengthen Nordic pandemic preparedness, promote vaccine equity, and advance CEPI’s #100daysmission.
🧬 Prof. Nicaise Ndembi, Regional Director for IVI, spoke at the Genomic Frontiers: RWANDA 2025 Symposium, highlighting how data and AI-driven predictive models can help forecast pandemics, strengthen preparedness, and guide timely health responses. 💡🌍
Rwanda continues to set an example in leveraging innovation for global health resilience. 🇷🇼
A warm welcome to Ambassador Patricio Esteban Troya Suárez and Mr. Orlin Manuel Madrid Cepeda from @EmbajadaEcuKOR to @IVIHeadquarters. We look forward to expanding Ecuador-IVI collaboration to strengthen regional capacity and drive innovation in vaccine R&D. 🇪🇨
Strengthening the global vaccine workforce for a healthier future.
IVI kicks off the Introductory Course for Standard Practice in Seoul under @WHO@mohwpr Global Training Hub for Biomanufacturing, uniting together 210+ participants from 39 countries.
IVI hosted a special class with Goodwill Ambassador Hyerim Woo, Taekwondo Master Mincheol Shin, and their son Siwoo—connecting the power of vaccines with the spirit of this martial art.
Bold ideas and innovations are shaping the future of vaccines—protecting health at every stage of life.
At #worldvaccinecongress Europe, @drjeromekim1 moderated a panel of global experts on technologies driving progress toward sustainable and inclusive immunization for all.
A major step for global health innovation! The Hong Kong Jockey Club Global Health Institute, a partnership between @HKUniversity, @Cambridge_Uni, and @IVIHeadquarters, was officially inaugurated with a plaque-unveiling ceremony at @hkumed
Africa is poised to lead in vaccines, from innovation to production. A new IVI-led study maps the continent’s vaccine ecosystem—R&D funding, clinical trials, regulatory readiness, and manufacturing capacity—and highlights paths toward self-reliance and health security.
A warm welcome to Head of Health Emergency Readiness Canada @ISED_CA Ritu Banerjee at @IVIHeadquarters. We look forward to continue working closely with partners in Canada to amplify the impact of safe, effective, and affordable vaccines against emerging health threats.
Building stronger vaccine systems starts with local expertise.
IVI proudly concludes the IVI fellowships of two Malaysia Ministry of Health professionals, strengthening global capacity for vaccine R&D and self-sufficiency.
IVI welcomed for a visit 32 fellows from 10 countries across Africa and Asia from the Dr. Lee Jong-wook Fellowship Program, supported by the Korea Foundation for International Healthcare.
Sharing insights to strengthen global health and vaccine capacity. 🌍
This year’s International Vaccinology Course brought together global researchers, policymakers, and health leaders united by one goal: getting vaccines to those who need them most.
Meet IVI at the #worldvaccinecongress Europe 🇳🇱. @drjeromekim1 delivers keynote remarks, and Dr. Manki Song joins a panel on the Korean ARPA-H project.
Swing by our booth to learn how IVI drives vaccine equity and pandemic preparedness.
Happy Chuseok from Seoul and the International Vaccine Institute headquarters! 🌾✨
As we celebrate the mid-autumn Korean harvest festival, we wish health, joy, and prosperity to you and your loved ones—a reminder of the healthier world we strive for.
We are grateful for P.S. Shaukat Abdulrazak and Kenya’s continued support and look forward to the country playing a key role in important initiatives to advance global health and a healthier future for all.
Kenya stands to be well placed as a regional hub with cutting edge facilities in vaccine production @KEMRI_Kenya@primateresearch among others in the shared vision of a healthier world made possible by vaccination, available to everyone, everywhere. We had interesting interactions with the Deputy Director General, Global Affairs and Communications at International Vaccine Institute Douglas N. Shaffer @IVIHeadquarters who is also the Special Envoy for Global Health Diplomacy 🇰🇷 . I assured him of the our 🇰🇪 commitment to be part and parcel of the global agenda in production of vaccines @Kenya_aist@ScienceRI_Kenya@nacosti@nrfkenya@KENIAupdates@OfficePCS_KE@KenyaSeoul
IVI’s @drjeromekim1 and team had the privilege of meeting with H.E. Abdulla Saif Al Nuaimi, Ambassador @UAEEmbassyROK. We look forward to driving vaccine innovation and sustainable global health outcomes with Emirati partners. 🇦🇪
Aligned teams, training, and collaboration are key to defeating cholera.
The Biovac OCV-S investigators’ meeting in Cape Town prepared the ground for the Phase I/III trial of Africa’s first end-to-end oral cholera vaccine. 🌍💉
Visionary leadership can turn bold ideas into global impact.
IVI honors Prof. John D. Clemens, our Founding Director General, with the 2025 Founders Medal for transforming IVI into a global force in vaccine science.
A heartfelt thank you to H.E. Bernadette Therese C. Fernandez 🇵🇭, newly appointed Ambassador @PHLinKorea, for welcoming the IVI team led by Dr. Douglas Shaffer. We are excited to work together to advance safe, effective, and affordable vaccines for everyone, everywhere.
Great progress in the collaboration btn KAVI-ICR n @IVIHeadquarters in vaccine research. This marks an important milestone in global efforts to advance cholera prevention n improve public health outcomes. Looking forward to the outcomes of this Phase 2 study. #vaccinedevelopment
Strengthening Regulatory Frameworks and Vaccine Production Capacity/Building Partnerships for Vaccine R&D.
Led by @IVIHeadquarters, this session explores how robust regulatory systems, production capacity, and partnerships can accelerate vaccine development and strengthen West Africa’s health security.
📣We're providing up to $10.4 million to work with global partners and gather real-world insights into the use of the Lc16m8 vaccine in protecting against mpox in the DRC.
IVI brought researchers together in Nairobi to prepare for the Phase II trial of the cholera conjugate vaccine—an injectable designed to protect even the youngest children.
China has been a valued IVI founding state party, and we look forward to strengthening collaboration to advance vaccines for a healthier future for all.
The International Vaccine Institute is proud to join @WHO Coalition of Interested Parties Network, a global collaboration to strengthen regulatory systems and improve access to safe, effective, and quality vaccines worldwide.
The 24th IVI International Vaccinology Course is underway in Seoul 🇰🇷 Kigali 🇷🇼 Stockholm 🇸🇪! Live lectures and Q&As link us in real time—sharing ideas and local perspectives on this year's theme "Vaccines in a Changing World: Innovation and Access."
Strong partnerships drive progress in global health. 🌍
IVI’s @drjeromekim1 and Saskatchewan Minister @wkaeding and Dir. Gerdts extended the MOU with @VIDOInterVac to advance infectious disease R&D, exchange, and training—working together for vaccines.
International Vaccine Institute (IVI) reposted
ECOWAS Lassa Fever International Conference@ECOWAS_LIC
As the conference begins Monday, 8 Sept 2025, mark your calendar for @IVIHeadquarters & RVMC’s side event on Thursday, 11th Sept 2025, as they discuss how strong regulatory frameworks and local capacity can accelerate vaccine R&D in West Africa.
We’re building the Nordic Vaccine Directory, a compilation of organizations advancing vaccine R&D, clinical trials, regulation, and manufacturing across 🇳🇴 🇸🇪 🇫🇮 🇩🇰 🇮🇸
Enroll your organization to help shape an integrated ecosystem for the region and strengthen collaboration.
During the 75th WHO Africa Regional Committee session, IVI's @drjeromekim1 joined leaders to highlight the role of Africa-led R&D in building a resilient biotech sector.
In Putrajaya, an IVI team led by Dr. Douglas Shaffer met with Dr. Mohd Azlan Bin Zaharudin, Director of MVPO, along with representatives from @officialmosti, @KKMPutrajaya, @NibmMalaysia, and industry to explore pathways for strengthened IVI-Malaysia collaboration 🇲🇾
At @Kemdikdasmen in Jakarta, IVI Director General @drjeromekim1 and delegation met with 🇮🇩 Minister of Health H.E. Budi Gunadi Sadikin to discuss strengthening collaboration on vaccine innovation and capacity-building for regional and global health.
This week in Bangkok, IVI joined the @ASEAN Meeting on Vaccine Security & Self-Reliance (AVSSR) and co-organized a training with Thailand's National Vaccine Institute and ASEAN country representatives to strengthen regional cooperation for epidemic/pandemic preparedness.
"Building on recent engagement with Brazilian health and science authorities, IVI aims to support collaborative initiatives aimed at accelerating the development of vaccines, diagnostics, and medicines in emerging economies, including Brazil"
As @BillGates visits South Korea, he highlights Korea’s journey from post-war poverty to global health leadership—citing the establishment of IVI in Seoul and Korean manufacturers driving vaccine development and access worldwide.
Health tech funds accelerate vaccines, diagnostics & medicines while fostering local innovation. Prof. Sue Ann Costa Clemens and I spoke with @VEJA about creating such a fund in Brazil to develop equitable, resilient & sustainable health technologies.
IVI's own Dr. @SushantSahastr1 makes a cameo in Korea’s latest box-office hit My Daughter is a Zombie! 🎬
He plays “Dr. Sushant,” a scientist with the clue to stopping a zombie virus—a playful nod to his real-life work leading vaccine research that protects millions worldwide.
Polio vaccine heroes Prof. Pierre van Damme (@UAntwerpen) & Dr. Ananda S Bandyopadhyay @anandaonline (@gatesfoundation), winners of the IVI-SK bioscience Park MahnHoon Award, were interviewed at IVI HQ on their groundbreaking work on #nopv2 ⤵️
We are proud that Prof. Nicaise Ndembi, Deputy Director General of IVI's Africa Regional Office, was named among the 100 Most Notable Peace Icons in Africa!
We applaud his leadership in vaccine research, public health, and development in Africa.
🔔 Apply by 23 July for the 2025 Introductory Course for Standard Practice by GTH-B.
This 3-week training offers a deep dive into the international standards that guide vaccine and biomedical product development as well as biosafety essentials.
IVI and Vaccinopolis @UAntwerpen partner to advance vaccine R&D for global health.
Combining our complementary expertise in epidemiology, translational clinical research, and capacity-building, we aim to accelerate the development of safe, effective, and affordable vaccines.
With a shared vision for health equity, IVI met with 🇧🇷 Minister of Health @padilhando and leadership to strengthen decades of vaccine collaboration and explore new opportunities.
We’ve just released a new documentary series showcasing our work in Nepal to advance clinical research. The films highlight the people behind the progress, working together to make life-saving vaccines a reality for vulnerable communities: Watch here: www.ivi.int/enhancing-nepals-potential-accelerating-life-…
This week at #africahealthexcon, IVI and @UPA_Egypt signed an MOU to promote equitable access to health technologies.
The partnership will focus on capacity building, technology transfer, and strengthening pooled procurement systems to support equity in regional public health.
As strategic partnerships remain central to our work, this afternoon a delegation from the International Vaccine Institute (IVI) visited Rwanda FDA for a discussion on deepening collaboration between IVI and Rwanda FDA.
What will it take to accelerate responses to emerging infectious diseases and pandemics?
IVI and the Korea Disease Control and Prevention Agency held the 2025 EuBiologics-IVI Global Vaccine Forum to explore the present and future of mRNA and other vaccine platform technologies.
IVI was featured on KBS2’s Return of Superman 🦸—one of Korea’s top TV shows!
Watch our new Goodwill Ambassadors, former K-pop star Hyerim Woo and her son Siwoo Shin, help spotlight IVI’s work toward vaccines for a healthier future. 🌍💉
Today, we kicked off the 2025 Introductory Course for Biologics Development and Manufacturing.
For the next 2 weeks, this year's cohort of 159 trainees will engage in lectures, case studies, and site visits to dive into all aspects of vaccine development and biomanufacturing.
The Ministry of Health has received a high-level delegation from the International Vaccine Institute (IVI) and the National Vaccine Institute as part of efforts to deepen collaboration between Ghana and the global vaccine research organization.
We’re honored to welcome Dr. Ilesh Jani as Chair of the GTFCC Steering Committee.
A renowned public health leader from Mozambique, Dr. Jani brings invaluable expertise that will drive momentum toward achieving the 2030 Roadmap to end cholera 🌍💧
IVI's 24th International Vaccinology Course is now open for general registration!
We invite researchers working or studying in vaccinology, biotechnology, public health, or a related field to join us 8-12 Sept 2025 in Seoul, Kigali, or Stockholm.
Congratulations to Dr. Delese Mimi Darko on her appointment as the first Director-General of the African Medicines Agency! As a member of IVI’s Scientific Advisory Group, Dr. Darko brings invaluable insight—and we look forward to continued collaboration with AMA.
Dr. Delese Mimi Darko, has been appointed as the first Director-General of the African Medicines Agency (AMA).She is renowned for her exemplary leadership as the Chief Executive Officer of the Ghana Food and Drugs Authority (FDA), brings a wealth of experience and a distinguished track record in regulatory excellence to her new role.
Her appointment signifies a bold step forward in strengthening regulatory oversight, promoting access to quality, safe, and efficacious medicines, and fostering pharmaceutical innovation across Africa.
We encourage technicians, engineers, scientists, and managers involved in biomanufacturing to join us for an intensive hands-on training course across vaccine research, development, and manufacturing.
An honor to meet with @GulfCDC and @GHC_GCC during #wha in Geneva. We discussed vaccine R&D, training, and future collaboration. Looking forward to advancing shared goals in global health together.
We were honored to welcome Dr. Youngmee Jee, Commissioner of Korea Disease Control and Prevention Agency and her team, to the IVI Europe Office in Stockholm on May 16. Thank you, Dr. Jee, for your support in advancing safe, affordable vaccines and global health security.
Join us next week at #wha78 in Geneva for a key event on leptospirosis—a neglected disease impacting vulnerable communities and worsened by climate change.
It was great to meet with Ambassador Eric Teo at the Embassy of Singapore in Seoul. We discussed possible avenues for joint research and development in global health, and we are excited to deepen the partnership between @IVIHeadquarters and Singapore.
Thank you, @Amb_EmmyKipsoi , Kenya’s Ambassador to Korea, for the warm welcome. IVI looks forward to building on our strong partnership and continued collaboration in vaccine research, development, and manufacturing.
Thank you Ambassador Nkubito, Rwanda’s Ambassador to Korea, for the warm welcome and continued support. IVI looks forward to deepening our partnership.
Embassy of Rwanda in Korea, Cambodia and Laos@RwandainKorea
Delighted to receive Dr. Douglas Shaffer, Deputy Director General of Global Affairs & Communications at the @IVIHeadquarters , along with Mr. Ondari D. Mogeni, Government Relations Manager for Africa, and Ms. Jael C. Cheruiyot, Global Affairs and Digital Communications Administrator.
Grateful for the meaningful exchange and shared commitment to global health. We look forward to further collaboration between Rwanda and IVI. 🤝
Group A Strep can cause rheumatic heart disease which threatens millions of lives, especially in low- and middle-income countries where treatment is scarce.
Potentially life-saving vaccine development is underway.
A pleasure to welcome Ambassador Sara Solís Castañeda @EmbaguateCorea back to IVI!
We had a meaningful and engaging discussion, highlighting opportunities for collaboration. We look forward to building a strong partnership with Guatemala ahead! 🇬🇹
We are happy to welcome Dr. Kerstin Westritschnig to IVI as the Head of our Austria Country Office. With 20+ years of experience in vaccine development, Dr. Westritschnig will play a key role in supporting our mission to discover, develop, and deliver vaccines for global health.
We are pleased to announce three new appointments to IVI's Board of Trustees. Prof. Helen Rees, Dr. Dominique Limet, and Dr. Nanette Cocero will begin their terms in 2026, ensuring the continued strength of IVI’s decision-making body. Learn more about these remarkable leaders ⤵️
We're very happy to welcome H.E. Bruno Jans, Ambassador of Belgium to the Republic of Korea, to IVI HQ for an introduction to our work accelerating vaccine science for global health impact.
At #ahaic2025 in Kigali, I had a great briefing with Dr. Nicaise Ndembi, Deputy DG & Head of Mission, @IVIHeadquarters Rwanda.
🌍 IVI’s Africa Regional Office is officially being established in Rwanda—marking a major milestone for: ✅ Strengthening vaccine R&D & manufacturing ✅ Deepening African-led innovation & policy coordination ✅ Expanding training & partnerships across the continent
Today marks the start of a two-week training workshop on clinical trials for drugs/ vaccines, aimed at strengthening the education and training of 22 healthcare professionals and scientists, particularly in clinical trials and biomedical research.
This initiative aligns with #rwanda’s efforts to advance innovation, #biotechnology, and #biomanufacturing, reinforcing its aspiration to become a leading hub for healthcare innovation in #africa.
Jihee Lee and Daseul Kim from @KoreaDCA completed the IVI Fellowship Program, contributing to global epidemiological research. They attended workshops in Ghana & DRC, gaining insights into infectious disease response & global cooperation 🌍
IVI is working to strengthen sustainable vaccine production for a healthier future for all
Join @wlpforum2025, featuring IVI Africa’s Dr. Nicaise Ndembi on the panel: Overcoming Challenges in the Sustainable Production of Vaccines and Biologics
Strengthening healthcare through local production and technology transfer. The 3rd WLPF is the premier global platform dedicated to transforming healthcare accessibility through sustainable local production and technology transfer. Join leading policymakers, industry pioneers, and health experts as they discuss innovative solutions to bridge supply chain gaps, boost manufacturing capacity, and advance equitable healthcare.
Your presence matters—Register now to be part of the change!
We are pleased to announce the appointment of two distinguished leaders in global health, @DrSethBerkley and Dr. Srishti Gupta, to IVI's Board of Trustees.
Do you work in the production of vaccines and other bio-products in an LMIC?
We invite you to apply for the 2025 Intro Course for Biologics Development & Manufacturing organized by GTH-B—a free, 2-week, on-site training program in Korea.
Officials from the International Vaccine Institute (@IVIHeadquarters ) visited @BioVaxInstitute as part of ongoing engagements to support the establishment of a Smart Vaccine Facility in Kenya. The discussions focused on gathering information to facilitate the facility's planning, ensuring that all necessary technical and logistical considerations are well understood. The meeting also delved into the general status of the initiative, including key investigations related to site selection, infrastructure, and regulatory requirements necessary for the project's success.
A significant portion of the discussions centered on capacity-building initiatives for biomanufacturing, highlighting the need for specialized training programs and partnerships to enhance local expertise. The IVI delegation and BioVax leadership explored collaborative opportunities to strengthen Kenya's vaccine production capabilities, aligning with national and global health priorities. The meeting underscored the shared commitment to advancing vaccine self-sufficiency in the region through strategic investments in technology, infrastructure, and human capital development.
Earlier today, on the sidelines of the 38th @_AfricanUnion Summit in Addis Ababa, Minister @nsanzimanasabin participated in a session on "Sustainable Access to Vaccines: Strengthening Regulatory Frameworks, Building Production Capacity, and the Importance of Partnerships in Achieving AU Priorities." Co-hosted by the Ministry of Health, @IVIHeadquarters, and the African Medicine Agency (AMA), the session brought together key stakeholders to drive collective action toward a stronger, resilient vaccine ecosystem in Africa.
Great to feel the determination in the room to drive forward the continent’s aspirations on sustainable vaccine manufacturing. Much work still to do, but we are moving!
Today, on the sidelines of the 38th Assembly of the @_AfricanUnion, we’re gathering African health leaders and industry experts to advance strategies for sustainable vaccine manufacturing and self-sufficiency in Africa 💉🌍
🇪🇹🇰🇪Today, @BioVaxInstitute is honoured to participate in the Ministerial Side Event on the margins of the 38th Ordinary Session of the Assembly of the African Union (@_AfricanUnion) under the theme "Sustainable Access to Vaccines: Strengthening Regulatory Frameworks, Building Production Capacity, and the Importance of Partnerships in Achieving AU Priorities." The event is currently taking place at the Sheraton Addis Hotel in Ethiopia.
In her remarks, while representing Dr. @DeboraBarasa, the @MOH_Kenya Cabinet Secretary for Health, Dr. Serah @Muteru03 , the GM of Regulatory Affairs- Kenya BioVax, emphasized the critical role of regulatory harmonization, capacity building, and strategic partnerships in shaping Africa's vaccine manufacturing ecosystem. As the investment in local production grows, Africa has a unique opportunity to achieve vaccine self-sufficiency.
We extend our gratitude to the @MOH_Kenya for its unwavering support and the International Vaccine Institute (@IVIHeadquarters ) for fostering key partnerships in this journey towards a resilient and self-sufficient vaccine manufacturing ecosystem.
Today, on the sidelines of the 38th Assembly of the @_AfricanUnion, we’re gathering African health leaders and industry experts to advance strategies for sustainable vaccine manufacturing and self-sufficiency in Africa 💉🌍
International Vaccine Institute (IVI) reposted
AU Health,Humanitarian Affairs&Social Development@AU_HHS
H.E @AmbSamate on the sidelines of the #38ausummit met with the Director General of @IVIHeadquarters @drjeromekim1. They had a fruitful conversation regarding the significance of vaccines in building a healthy environment and a prosperous future for all.
📣 Call for participation and abstracts: The 2025 Vaccines for Enteric Diseases (VED) conference will be held 24-26 June 2025 at the Wallenberg Conference Centre in Gothenburg, Sweden in conjunction with @goteborgsuni
Int. Centre for Antimicrobial Resistance Solutions@ICARS_global
📄 Today's #mondayread is a paper on #vaccines & #amr that analyses the funding landscape for human bacterial vaccines in low- and middle-income countries (LMICs).
Key findings:
💰 Funding disparity: Between 2007 and 2024, the Global North received the majority of human bacterial vaccine funding, while the Global South received less than 20% of the total.
🌎 Geographic misalignment: There is a mismatch between funding distribution and the burden of antimicrobial resistance (AMR).
📊 Data gaps: Current tracking lacks details on final funding recipients, hindering full assessment of inequities.
📉 Low domestic investment: Limited investment from LMICs further complicates efforts to address funding disparities.
🔎 Funding focus: Most funding targeted M. tuberculosis and S. pneumoniae, with critical gaps in R&D funding for WHO AMR priority pathogens.
💉Need for transparency: Transparent tracking, reporting, and allocation of vaccine R&D funding are essential for tackling AMR and addressing global health challenges effectively.
New analysis in @NEJM describes changes in the epidemiology of mpox cases in Africa leading up to/after the 2024 declaration of mpox as a public health emergency in Africa and worldwide
Read more from IVI's Africa Regional Director Dr. Nicaise Ndembi and @AfricaCDC colleagues⤵️
We are proud to partner with @CEPIvaccines and Afrigen Biologics to develop the first-ever mRNA-based vaccine for Rift Valley fever, which poses a significant threat to people across Africa and the Middle East.
Together, we can accelerate vaccines for a healthier future.
New findings published in @LancetMicrobe suggest the potential for sustained, long-term protection by oral cholera vaccines in populations with endemic cholera ⤵️
At our annual Global Council meeting, IVI and the Government of Thailand brought to attention the global health importance of #leptospirosis and an action plan forward to designate the disease an official WHO Neglected Tropical Disease.
IVI started leading an international consortium of researchers to develop a vaccine using what we know about existing COVID-19 variants and how they function to potentially protect against future mutations and even other deadly coronaviruses.
We held IVI's flagship Vaccinology Course at three sites this year—Seoul, Stockholm, and Kigali—with a theme of Vaccine to Vaccination: from Science to Society. A total of 186 trainees representing 39 different nationalities participated in the five-day course worldwide!
From all of us at IVI: we wish you and your loved ones a healthy and joyful holiday season. Thank you for another year of inspiring collaboration and progress toward a future free of vaccine-preventable infectious diseases!
We were honored to host a delegation from Japan’s National Center for Global Health and Medicine (@NCGM1868) and the National Institute of Infectious Diseases. Thank you for the insightful discussions and the opportunity to explore collaborations on vaccine R&D!
GoK and IVI MoU Signing Ceremony : A Bold Step Towards Vaccine Independence
This morning, the @GovtOfKenya (GoK), through the @MOH_Kenya , and the @IVIHeadquarters (IVI), inked a historic Memorandum of Understanding (#mou) at Afya House. The ceremony marks Kenya's commitment to enhancing vaccine research, development, and manufacturing capacity, underscoring the country's aspiration for self-reliance in vaccine production. Key dignitaries, including Dr @DeboraBarasa, Cabinet Secretary for Health, and Dr @drjeromekim1, IVI's Director General, emphasized the importance of this partnership in achieving universal health coverage and bolstering public health infrastructure.
This collaboration, which stems from Kenya's accession to IVI as its 41st member state earlier this year, paves the way for groundbreaking research, workforce development, and technology transfer initiatives. It aligns with Kenya's strategic vision of leveraging partnerships to establish local vaccine manufacturing capabilities through institutions like the @BioVaxInstitute and @KEMRI_Kenya. Dr Michael Lusiola, CEO of BioVax, hailed the MoU as a "game-changer" for Africa's vaccine ecosystem.
The signing of the MoU reflects the shared vision of a healthier future for Kenya 🇰🇪and the globe 🌍. With this milestone, Kenya stands ready to address vaccine accessibility challenges, building on lessons from the COVID-19 pandemic and leading the charge for a resilient and self-sufficient biomedical sector in Africa.
This morning, I joined my CS @MOH_Kenya@DeboraBarasa during the signing ceremony of an MOU between @MOH_Kenya and @IVIHeadquarters (IVI). This historic MOU ushers in a new era of enhanced vaccine research, development, and manufacturing capacity in the country as we aspire.....
Today, we marked a historic milestone in advancing vaccine development and health security for Kenya and the region.
I had the privilege of presiding over the signing of a Memorandum of Understanding between the Government of Kenya and the International Vaccine Institute (IVI) at Afya House. This partnership reaffirms our commitment to strengthening vaccine research, innovation, and production capacities to tackle critical public health challenges.
With Kenya selected to host IVI’s Country Office and the Advancing Vaccine End-to-End Capabilities (AVEC) Project Office, we are positioning our country as a leader in vaccine innovation across Africa. This initiative aligns with the Africa CDC’s goal of producing 60% of the continent’s vaccines locally by 2040.
As I stated during the event, “This collaboration is a transformative step toward building a robust vaccine ecosystem, ensuring equitable access for all, and strengthening health security for Kenya and the region.”
I extend my gratitude to IVI’s Director General, Dr. Jerome Kim, and our dedicated team, including PS Harry Kimtai, DG Health Dr. Patrick Amoth, and the entire Ministry of Health, for their unwavering commitment. Together, we will drive innovation, expand vaccine access, and build resilient health systems that can effectively respond to future health challenges.
We are extremely pleased to sign an MOU with the Government of Kenya to establish and operationalize IVI’s Country and AVEC Africa Project Office in Kenya.
Director General @drjeromekim1 and Cabinet Secretary for Health Dr. @DeboraBarasa exchanged the MOU in Nairobi yesterday.
"We are fortunate to have the strong support of the Kenyan Government to realize the goals of AVEC Africa: a whole-of-continent approach to activate end-to-end vaccine projects based on local and regional need."
“Together, we will continue building and connecting a project-driven network of partners to power an integrated and sustainable vaccine ecosystem meeting the needs of Kenya, the region, the continent, and beyond.”
🗨️ Dr. Douglas Shaffer, DDG and Ag. Africa Regional Director
We are thrilled to announce the completion of a Host Country Agreement with the Rwandan Government to establish IVI's Africa Regional Office in Rwanda 🇷🇼
Today, Minister @NsanzimanaSabin and Dr. Jerome H. Kim, Director General of @IVIHeadquarters, signed a Host Country Agreement to establish the headquarters of International Vaccine Institute (IVI) Africa Office in Rwanda.
This milestone marks a significant step toward the sustained advancement of healthcare research and equitable access to vaccines across the continent and beyond.
"We are excited to join the growing vaccine research and development ecosystem and biomanufacturing partners in Africa to build local, sustainable vaccine production capacity towards a goal of independent, continental health security."
"As IVI’s focal point for the continent, this office will play a critical role in expanding IVI’s member base and engagements in addition to catalyzing regional collaborations across the vaccine ecosystem."
🗨️ Dr. Douglas Shaffer, DDG and Ag. Africa Regional Director
Congratulations to 155 newly certified participants who completed the 2024 Intro Course for Standard Practice (GxP) 👏
This program trains across essential skills required to develop/produce biopharmaceuticals such as vaccines and therapeutics according to current GxP standards.
Topics range from Good Manufacturing Practice, Good Laboratory Practice, Good Clinical Practice, and Good Clinical Laboratory Practice as well as Quality Management, Biosafety, Technology Transfer, and Vaccine Epidemiology.
We are pleased to share highlights of the recent benchmarking visit by officials from @IVIHeadquarters, @FMC_Owo, @ATBUTHINFO, Kenema Gov't Hospital, & UNC Phebe to our Unit, to explore our best practices in #clinicalresearch.
AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antibiotics and other antimicrobials. Infections then become difficult—or even impossible—to treat.
This past week, we’ve had the pleasure of hosting a delegation from Bhutan, reflecting on and charting a path forward for our work to capture data on #amr at national and regional levels while also discussing our member state relations 🇧🇹
IVI and Thailand’s National Vaccine Institute (NVI) renewed its Partnership Agreement to pursue collaborative and capacity-building activities for another year 🤝
NVI Director Dr Nakorn Premsri and @drjeromekim1 signed + exchanged the agreement during a Board meeting at HQ today
It's SAG week at IVI! Which means our researchers across the institute, from laboratory science to clinical development to epidemiology, present their ongoing research to members of our Scientific Advisory Group and seek feedback and future direction.
Last week, we joined partners including @AfricaCDC and @OoasWaho for a Research Preparedness Ecosystem Engagement Workshop in Accra, Ghana organised by @IVIHeadquarters with funding from @CEPIvaccines.
We are excited to announce that IVI has appointed Dr. Nicaise Ndembi as Deputy Director General of our Africa Regional Office, based in Kigali, Rwanda!
Dr Ndembi, currently serving as Principal Advisor to the @AfricaCDC’s Director General and Deputy Incident Manager Mpox – Marburg Continental Preparedness and Response Plan for Africa, will assume this new role on January 1, 2025.
Dr Ndembi shared: “I’m excited to work with this exceptional team that is so committed to advancing end-to-end vaccine manufacturing in Africa with a lasting impact on global public health. It’s such a pleasure and a privilege to be with IVI in my new capacity as DDG"
IVI and @ICMRDELHI co-organized a roundtable meeting in New Delhi, inviting scientists and industry experts to speak on "Advancing Pandemic Preparedness with Plug-and-Play Vaccine Platforms in India"
Congratulations to our researchers and colleagues @LSHTM and beyond for this new publication in @Els_Vaccine: “#chikungunya vaccine development, challenges, and pathway toward public health impact"
In Kenya, IVI’s DDG Dr. Douglas Shaffer met with Dr. Peter Gichuhi Mwethera, DG of @primateresearch, and held productive discussions with Dr. Lucy Ochola and her team on potential collaborations. Thank you for the warm welcome and insightful exchange!
We were pleased to welcome the @NCDCgov delegation to IVI headquarters during their visit to Korea as part of the KOICA Fellowship Program. Thank you for learning more about our work across the vaccine spectrum, and we look forward to forging impactful partnerships.
On the margins of #isv2024, where IVI proudly partnered with @Int_S_Vaccines, we had the pleasure of inviting congress participants to our headquarters to connect with our scientists and explore avenues for collaboration and funding. A big thank you to everyone who joined us!
The 2024 Introductory GxP Course offered by GTH-B @mohwpr kicked off today, bringing together trainees and faculty members from around the world for a 3-week program covering the basics of quality standards and biosafety protocols for biomanufacturing ⤵️ www.ivi.int/ivi-conducts-2024-introductory-course-for-sta…
An insightful and inspiring Stanley Plotkin lecture by @drjeromekim1 Director General @IVIHeadquarters on how advancement of partner-led collaboration aims to build end-to-end capacity and sustainability of vaccine R&D and manufacturing ecosystem in Africa @AfricaCDC#isv2024
We were pleased to welcome @SaniaNishtar, Karin Tegmark Wisell and the @Gavi delegation to IVI’s Europe Regional Office. We look forward to strengthening IVI-Gavi collaboration to advance vaccine equity. Big thanks to @SweMFA for organizing the visit. #vaccinessavelives#gavi
We celebrate the news that EuBiologics shipped the first batch of Euvichol-S, a simplified oral cholera vaccine we developed in collaboration with the manufacturer 👏
Over 1 million doses were sent to Niger to help prevent and control #cholera outbreaks
Dr. Carlos Gabriel Alvarenga Cardoza, Vice Minister for Policies and Health Management, led a delegation of health officials to IVI and raised the flag of El Salvador during the accession ceremony.
Strep A Vaccine Global Consortium (#savac) and @WHO gathered major stakeholders in London to address gaps in existing research and evidence to progress the #strepavaccines policy agenda
Following the #iviglobalcouncil Meeting, IVI's member delegates had a great opportunity to visit Thailand's Government Pharmaceutical Organization and tour its vaccine production facilities, from the hatching plant to packaging and quality assurance. Thank you @gpoth_official!
IVI held its second annual face-to-face Global Council meeting in Bangkok, gathering State Party representatives to review our strategic priorities and discuss pathways forward for local/regional/global vaccine development and implementation.
The #iviglobalcouncil Meeting agenda included a special report on IVI’s activities in Africa, remarks and recommendations from State Party representatives, and a request to support the inclusion of #leptospirosis on the @WHO list of neglected tropical diseases (NTDs).
We are thrilled to co-host #ivc2024: Kigali with @Uni_Rwanda, bringing together 80+ trainees including 30 participants from East African Community partner states with support from @EacRceVihscm
Learn more about IVI's work in Rwanda to build vaccine education and development ⤵️
For the first time in 23 years, the International Vaccinology Course – organised by the International Vaccine Institute (IVI) – is being held in Africa.
@Uni-Rwanda is hosting the course, which is also simultaneously taking place in Korea and Sweden.
By collaborating with SK Bioscience, a global leader in vaccine production, @BioVaxInstitute gains access to cutting-edge technology and expertise in the production of high-quality vaccines. This partnership will not only enhance Kenya's capacity to manufacture vaccines locally but also contribute to the development of innovative vaccines tailored to Africa's unique health challenges. In addition, @atkinsrealis , a renowned infrastructure firm, will offer technical support in the design and construction of state-of-the-art vaccine manufacturing facilities, ensuring that @BioVaxInstitute operates efficiently and at global standards.
The involvement of the @IVIHeadquarters further strengthens this partnership by providing research support and expertise in vaccine development, clinical trials, and regulatory approvals. IVI’s global network and experience will facilitate knowledge transfer, ensuring that @BioVaxInstitute becomes a key player in Africa’s vaccine landscape. This collaboration is poised to accelerate vaccine accessibility in Kenya and across the continent, improving public health outcomes and reducing reliance on imported vaccines. Furthermore, it positions Kenya as a regional hub for vaccine production, fostering economic growth and supporting long-term health security. #africanvaccinemanufacturing#vaccinesforall
Feasibility study to establish a Smart Vaccine Manufacturing Facility Project in Kenya
A team of experts from South Korea 🇰🇷 visited the @BioVaxInstitute to conduct a comprehensive feasibility study on establishing a smart vaccine manufacturing facility in Kenya 🇰🇪. The visit marks a significant milestone in the ongoing collaboration between Kenya and South Korea in the health, innovation and biotechnology sectors. The team, comprising leading scientists, engineers, and industry specialists from #skbioscience, @atkinsrealis and @IVIHeadquarters, aims to assess the viability of building a state-of-the-art facility that will enhance Kenya's capacity to produce vaccines locally and strengthen the country's health security.
During the visit, the Korean delegation met with officials from @BioVaxInstitute, @MOH_Kenya, @NDUKenya, @IGADsecretariat, @nqclab, @primateresearch, @kevevapi, @KEMRI_Kenya, @USPGlobalHealth , @DiscoverJKUAT, @ppbkenya and @konzatech among others. They discussed the potential benefits of a smart manufacturing facility, which could catapult Kenya into a leadership position in vaccine production. The proposed project is expected to leverage advanced technologies such as artificial intelligence and automation to streamline #vaccine production processes, increase efficiency, and reduce costs. This initiative aligns with Kenya's broader goal of becoming a regional leader in vaccine production, reducing reliance on imported vaccines and improving access to life-saving immunizations for millions of people.
The feasibility study will explore key factors such as infrastructure, regulatory frameworks, and potential partnerships with local and international stakeholders. If successful, the smart vaccine manufacturing facility could position Kenya as a hub for vaccine innovation and production in Africa, driving economic growth and improving public health outcomes across the continent. The project has received strong support from the Kenyan government and the South Korean partners, who are keen to strengthen bilateral relations through this transformative venture. #africanvaccinemanufacturing#vaccinesforall#siliconsavannah
This year, we awarded scholarships to 13 health professionals from @icmrdelhi@NVITH_Official & @DOHgovph to attend #ivc2024 in Seoul, made possible by generous contributions from the Governments of 🇮🇳 🇹🇭 🇵🇭
We're grateful for this support to build local knowledge and capacity!
While in Kigali for #ivc2024, IVI's DDG of Global Affairs & Communications Douglas Shaffer met with @USAmbRwanda Eric W. Kneedler to share progress on IVI's research collaborations in Africa and our work to support a continental vaccine manufacturing ecosystem 💉🌍
We are thrilled to co-host #ivc2024: Kigali with @Uni_Rwanda, bringing together 80+ trainees including 30 participants from East African Community partner states with support from @EacRceVihscm
Learn more about IVI's work in Rwanda to build vaccine education and development ⤵️
For the first time in 23 years, the International Vaccinology Course – organised by the International Vaccine Institute (IVI) – is being held in Africa.
@Uni-Rwanda is hosting the course, which is also simultaneously taking place in Korea and Sweden.
Day 1 of the IVI 23rd International Vaccinology Course (IVC) in Kigali was a success! Thanks to our guest speakers, participants, and expert lecturers for an impactful start of the 5-day program. Expert discussions today covered the key vaccine topics: - Basic Immunology & Biomarkers - Correlates of Protection - Vaccine Access & Equity - From Lab to Clinic: Vaccine Assessment. #ivivaccinology#vaccinetovaccination
Honored to host the @Sverigesriksdag Committee on Health and Welfare at IVI HQ during their official trip to Korea.
Special thanks to @SwedeninKR for their support, and we look forward to sustaining our longstanding collaboration with the Swedish life sciences ecosystem 🇸🇪
DG Prof. @emilebienvenu received Dr. Douglas N. Shaffer, the Deputy Director General of Global Affairs & Communications, and Dr. Anh Wartel, the Deputy Director General of Clinical, Assessment, Regulatory, and Evaluation, from @IVIHeadquarters. Their discussion centered on enhancing collaborations between IVI and Rwanda FDA.
And we asked Carlos Reina, an Epidemiologist and Vaccinology Fellow in Seoul, if there is an #ivc2024 lecture that he is particularly looking forward to ⤵️
Day 2 of #ivc2024 continues with Vaccinology Essentials, covering the phases of vaccine clinical development, infectious disease burden studies, the regulatory approval process, and vaccine hesitancy
Today, DVC SPA Dr. @Rayndikumana addressed participants from around the world attending the 23rd International Vaccinology Course, organized under the theme 'Vaccine to Vaccination: From Science to Society.' The event, held in partnership with the International Vaccine Institute (@IVIHeadquarters), aims to explore the fundamentals of vaccinology and the process of creating vaccines.
Over the next 5 days, participants will attend lectures, case studies, and site visits to rigorously engage in topics across #vaccinology and how vaccines are developed, tested, regulated, approved, and used.
This is Vaccine to Vaccination: from Science to Society 💉🌏
Day 1 of #ivc2024 is all about Vaccinology Essentials, from the history of vaccines, the different types of vaccines, basic immunology, correlates of protection, and how vaccines are assessed in the lab.
Exciting News! The long awaited @IVIHeadquarters 23rd Annual International Vaccinology Course (IVC) is happening from September 2-6, 2024, in Kigali for the very first time! This year’s course links 3 locations: IVI HQ in Seoul, in Stockholm with @karolinskainst and in Kigali, with @Uni_Rwanda, @EacRceVihscm. Over 200 participants from 81 countries, including EAC Partner States and about 100 from Kigali, will join the program to explore #vaccinology fundamentals, #vaccinedevelopment and more. Looking forward to a great week ahead! #vaccines#capacitybuilding#collaboration
A big welcome! To the @CEPIvaccines Investors Council who visited IVI today for a mini vaccinology course led by IVI senior scientists and our work across end-to-end vaccine development and delivery
Proud to announce that IVI won the Special Recognition for Vaccine Initiatives Award at the Korea BioPharma Excellence Awards🏆 Dr. Tarun Saluja and Dr. Sun Bean Kim represented IVI and received the award. Thank you to @IMAPAC for hosting this celebration of biopharma excellence!
IVI fully supports @WHO and @AfricaCDC’s declaration of #mpox as a health emergency. Deploying effective #vaccines against mpox is critical to stop its spread. By focusing on creating an effective vaccine solution, we can help prevent this #mpoxoutbreak from a new pandemic.
We were honored to host H.E. @jorgerojas2022, Colombia's Vice Minister of Foreign Affairs from @CancilleriaCo, to discuss Colombia's accession to IVI 🇨🇴 We look forward to collaborating within their emerging vaccine industry to advance research against neglected diseases.
Congratulations to IVI’s Ethiopia Cholera Control and Prevention team led by @DrSeEunPark and investigators @AHRI_ETH@EPHIEthiopia for the publication of this new supplement in @CIDJournal
Read their reflections & strategies for the Ethiopian National Cholera Elimination Plan⤵️
With better prevention, diagnosis, and treatment, we can save lives and make a hepatitis-free future a reality for all. Learn more about IVI's work to accelerate vaccines ⤵️
It was a pleasure to host The Honourable @melaniejoly, Minister of Foreign Affairs 🇨🇦 for an official visit to IVI HQ today, who announced Canada’s intention to join IVI.
The IVI BOT has approved this request, and we look forward to welcoming Canada as a State Party!
"Through its membership to the IVI, Canada will advance its global health priorities by complementing existing partnerships...to support global immunization and protect vulnerable populations against infectious diseases."
We are very grateful to Minister @melaniejoly, Ambassador of Canada to ROK @TamaraMawhinney, and officials from @GAC_Corporate and @CanEmbKorea for visiting us at IVI and sharing the Government of Canada’s enthusiasm for #vaccine science and global health impact 🇨🇦💉🌎
An IVI team led by @DrSeEunPark and partners @AHRI_ETH@EPHIEthiopia held the Ethiopia Cholera Control and Prevention (ECCP) Workshop in Hawassa to share knowledge, experiences, and guidance for the way forward across the multi-sector pillars of #cholera control in Ethiopia 🇪🇹
A study led by IVI and collaborators published in @LancetGH shows the immunogenicity and safety of Euvichol-S oral #cholera vaccine in a comparative Phase 3 trial conducted in Nepal.
Based on the results of this study, Euvichol-S achieved @WHO PQ earlier this year.
Last year, IVI and our global network of partners advanced vaccine candidates for emerging diseases, licensed new vaccines, organized trainings, and tackled emerging global health challenges such as AMR and climate change.
Thrilled to have leading experts at 2024 IVI Global Vaccine Forum. Thank you to KDCA for co-hosting the forum, Seoul Cyber University for supporting the IVI Forum series, and 140+ participants for attendance.
The IVI Global Council convened its 2024 Virtual Meeting yesterday, where Dr. Opart Karnkawinpong, Permanent Secretary @pr_moph of the Kingdom of Thailand, accepted an appointment as the council’s inaugural President for a two-year term. ⤵️
At the Global Forum for Vaccine Sovereignty and Innovation, Minister @CZacharopoulou@francediplo delivered a letter requesting France's membership to IVI to our Director General @drjeromekim1 🤝
On June 17th, IVI and @PasteurNetwork signed a landmark MoU in Paris to enhance global health initiatives. 🤝 "Together, we will drive innovation and accelerate life-saving vaccines for the most vulnerable people." - said Dr. @drjeromekim1, Director General, IVI.
IVI and @agenceANRS signed an MOU in Paris to foster high-quality clinical research. “This partnership will support the development of accessible, suitable, and affordable medical interventions to tackle infectious diseases in LMICs.” said @drjeromekim1, Director General, IVI.
In Kigali, IVI and @RwandaHealth exchanged an MOU to establish the IVI Africa Regional Office in Rwanda 🇷🇼
Minister of Health @nsanzimanasabin and DG @drjeromekim1 signed the MOU, signaling our partnership to build a hub for global health research, innovation, and collaboration.
Today, Minister @nsanzimanasabin and Dr Jerome H. Kim @drjeromekim1, Director General of the International Vaccine Institute, signed a Memorandum of Understanding (MoU) setting out the process for the establishment of the African Regional Office of the @IVIHeadquarters in Rwanda.
Kenya has formally joined the International Vaccine Institute (IVI) as a Member State, strengthening our country's resolve to achieve self-reliance in vaccine production.
Increased vaccine availability will enhance the delivery of our primary healthcare and disease prevention.
During the accession ceremony of Kenya at IVI headquarters in Seoul, South Korea, in the company of IVI Director-General Jerome Kim.
IVI committed to establish a Country and Project Office in Nairobi, which will be dedicated to the operations of its Advancing Vaccines End-to-End Capabilities (AVEC).
Thank you, Your Excellency Dr. @WilliamsRuto, for raising the Kenyan flag at IVI headquarters: we are proud to reach this milestone and look forward to working collaboratively toward our common goals.
On the margins of the Korea-Africa Summit, Minister of State @YvanButera participated in an event organized by @IVIHeadquarters, @KoreaDCA and @AfricaCDC on strengthening the vaccine manufacturing ecosystem in Africa. Rwanda hosts IVI’s Africa Regional Office.
On the sidelines of the #koreaafricasummit, IVI, @KoreaDCA and @AfricaCDC held a key dialogue today on enhancing vaccine access and health security in Africa, bringing together government officials, public health experts, and industry leaders to forge new partnerships.
Thanks for all ideas and inspiration at our #wha77 side event. The key message is clear: vaccines are a crucial tool in preventing AMR. We need to strengthen cooperation and support LMICs to avert AMR though vaccination. Together, we can enable a future where AMR is reversed.
Here's the lineup of our AMR-dedicated event that we are hosting right now in Geneva at the sidelines of #wha77 We are thankful to all the speakers and guests that have made it to this event.
We are looking forward to welcoming our speakers and guests later today to our event on the sidelines of #wha77, where we will discuss the crucial role of vaccines in addressing AMR in low- and middle-income countries.
We were pleased to welcome newly appointed AMB @KenyaSeoul H.E. @Amb_EmmyKipsoi to IVI HQ to discuss strengthening joint efforts to build capacity and resilience across vaccine ecosystems on the African continent. We look forward more robust collaborations in the future.
.@IVIHeadquarters will lead the research to test whether an mRNA vaccine candidate that has already undergone early assessment against Omicron, Delta and Alpha variants could be modified to also successfully protect against a broader array of viruses related to COVID-19.
A warm welcome to H.E. @ChafikRachadi, Ambassador of His Majesty the King of Morocco to the Republic of Korea @MoroccoInKOR. Thank you for the productive discussions on shared goals toward sustainable vaccine manufacturing and capacity-building across the African continent.
Save the dates 🔔 IVI's annual International Vaccinology Course will be held 2-6 September 2024 and we are now accepting applications for the IVI Vaccinology Fellowship!
Join us in Seoul (or online!) on the sidelines of the 2024 Korea-Africa Summit 🇰🇷🌍
Hosted by IVI, @KoreaDCA and @AfricaCDC, we aim to catalyze dialogue, collaboration, and collective action to enhance vaccine access and health security in Africa
Our @TexasChildrens Center for Vaccine Development + National School of Tropical Medicine @BCM_TropMed = excited to partner with the International Vaccine Institute @IVIHeadquarters based in Seoul Korea on vaccine training and capacity building in Latin America
We are happy to share that IVI established a new collaborative relationship with @bcmhouston and CRIVB AIP to strengthen capabilities in the vaccine sciences and the biopharmaceutical R&D industry in Panama and Latin America region 🌎
We are happy to share that IVI established a new collaborative relationship with @bcmhouston and CRIVB AIP to strengthen capabilities in the vaccine sciences and the biopharmaceutical R&D industry in Panama and Latin America region 🌎
IVI has now officially moved into its permanent Europe Regional Office in Stockholm 🇸🇪
On May 3, we held a ribbon-cutting ceremony with Diana Janse, State Secretary for International Development Cooperation & Foreign Trade @SweMFA, and other friends and supporters.
We are thankful to everyone who attended our scientific symposium, where we explored the crucial role of public-private partnerships in advancing vaccines for use in low-resource settings.
Prof. Jan Holmgren delivered a keynote talk on the history of #cholera vaccine 💉
Join us in Geneva on the sidelines of the 77th World Health Assembly 🌐
IVI is hosting an event in partnership with the Governments of 🇧🇹🇸🇻🇪🇹🇰🇷🇸🇪 to explore an alignment between national #vaccine strategies and efforts to combat #amr in LMICs
We are thrilled to welcome the Republic of El Salvador as our 40th member state 🇸🇻
We are grateful to the Government of El Salvador for its support and look forward to working closely together to make safe, effective, and affordable vaccines a reality for all.
Very pleased to welcome Ambassador @KumarAmitMEA from @IndiainROK to @IVIHeadquarters. Thank you for visiting us and for the enriching discussions on bolstering our collaboratives ties with India's vaccine and public health ecosystem. Looking forward to more collaborations ahead!
EVENT💉The international Vaccine Institute (@IVIHeadquarters) is hosting a scientific symposium on the topic “Using Public-Private Partnerships for Discovery, Development and Delivery of Vaccines” on 3rd May at 14:00-15.45 CEST🗣️ More info here⤵️ www.swedev.dev/event/symposium-using-public-private-partn…
We are thrilled to share a new film that features a personal account of the impact of #cholera and the BTS story of the public-private partnerships that made oral cholera vaccines available for global health!
Save the dates 🔔 IVI's annual International Vaccinology Course will be held 2-6 September 2024 and we are now accepting applications for the IVI Vaccinology Fellowship!
This year's course spans vaccine to vaccination: the basics of vaccinology and how vaccines are developed, tested, regulated, and approved while emphasizing their ultimate utility: vaccination 💉
A warm welcome to Ambassador @SaraSolisC@EmbaguateCorea to IVI HQ. We look forward to working closer together with the Government of Guatemala and partners to accelerate vaccines for regional and global health! 🇬🇹
Euvichol-S improves productivity by ~40% over Euvichol-Plus® (which currently supplies the global OCV stockpile) by modifying the formulation and manufacturing method of the original vaccine material
Are you passionate about #vaccines for global health and ready to help lead an international team of experts and advocates working toward a vision of a world free of infectious diseases?
IVI is looking to fill new leadership positions at HQ and our regional/country offices 👇
"The global stockpile has run completely dry, as deadly outbreaks of the disease continue to spread"
Learn more about IVI's partnerships with 3 vaccine manufacturers in S. Korea, S. Africa, and India to increase global volume of oral #cholera vaccine ⤵️
With #strepa vaccine candidates entering the clinic, now is the time to critically engage industry partners
At @vaccinenation, Strep A Vaccine Global Consortium (#savac) held a forum to help navigate barriers to investment in Strep A vaccines and how to enable next steps
Thank you for having us in this meaningful conversation about strengthening end-to-end capabilities across the vaccine value chain to build sustainable and resilient vaccine ecosystems in Africa.
IVI DG @drjeromekim1 and Deputy DG Dr. Anh Wartel had the opportunity to meet with Dr. Patricia Minaya Flores and Caroline Bussiere at @Sante_Gouv in Paris, France. Thank you for hosting us and we look forward to further collaboration and dialogue in the future!
Our pleasure to host Managing Director Sauro Vicini of @ClustER_Health and Ms. Sara D'Attore from @Arter_ER at @IVIHeadquarters during @RegioneER’s official visit to Korea. Thank you for learning about IVI and our work to make an impact on global health through vaccine science!
Last week, an IVI delegation had the honor of meeting with H.E. Cholnan Srikaew, Minister of Public Health, Dr. Opart Karnkawinpong, Permanent Secretary, and esteemed leaders of @pr_moph, as well as our long-time partner @NVITH_Official 🇹🇭
We extend a heartfelt gratitude to the Thai Government for their renewed support. Together, we're committed to bolstering pandemic resilience and fostering sustainable vaccine ecosystems across Southeast Asia and beyond. 🌏
This is IVI's sixth oral cholera vaccine technology transfer, with all of our partnerships leading to, or seeking to achieve, @WHO prequalification (PQ) to enable public procurement
IVI and BE will also pursue WHO PQ following national licensure in India
"The cholera situation is dire...especially as outbreaks increase and the global vaccine supply remains strained. With more manufacturers like @biological_e entering the market, the future supply situation looks strong"
🗨️ Dr. Julia Lynch, Director of IVI's Cholera Program
IVI joins Hilleman Laboratories, Chula VRC, and Mahidol Vivax Research Unit at the 4th mRNA Scientific Colloquium convened by @WHO and @MedsPatentPool, pledging collaboration on research consortia to accelerate mRNA vaccines against dengue and other priority pathogens
"Through this collaboration we hope to jointly develop a mRNA-based solution (for dengue) that can be shared, manufactured, and implemented throughout the region and globally."
Diagnosing #typhoid is challenging, but surveillance studies can help decision-makers to better understand typhoid burden in endemic countries! Read our latest blog to learn more about recent data on typhoid incidence across six African countries: www.coalitionagainsttyphoid.org/understanding-typhoid-bur…
📢 NEW research in @LancetGH shows a high burden of #typhoid fever in sub-Saharan African countries, indicating need for introduction of typhoid conjugate vaccines in endemic countries
There are ~12.5 to 16.3 million cases of #typhoid every year with ~140,000 deaths
However, with generic symptoms and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries
SKYTyphoid, a new #typhoid conjugate vaccine with @WHO prequalification, is a product of collaboration between IVI, #skbioscience, @gatesfoundation, and our state funders.
In other words, a successful product of a Product Development Partnership (PDP).
Happy International Women’s Day! Come and join us to celebrate Rwanda and Sweden’s gender equality achievements at our “Women in Action” event on March 16th 2024.
IVI joins hands with @NU_kouhou to collaborate on global vaccine research 🤝
We extend our gratitude to Nagasaki University President Prof. Takeshi Nagayasu for signing a MOU with @drjeromekim1, and to the NU delegation for visiting us at IVI HQ!
"The world has run out of cholera vaccines—just when the deadly disease is on a rampage not seen in many years," writes @pratikmpawar for @NewsfromScience
"But hope is on the horizon"
Learn more about IVI's work to develop new #cholera vaccines and increase the world's supply⤵️
The 24th International Conference on EID and 2nd International Symposium for Infectious Disease Research Institutes Cooperation kicked off today in Korea, bringing together the research and public health communities to address major global health issues and strengthen cooperation
International Vaccine Institute to open a new Country and Project Office in Kenya
@IVIHeadquarters (IVI) will launch a new Country and Project Office in Kenya to serve as the headquarters for IVI's Advancing Vaccine End-to-End Capabilities (AVEC) initiative in Africa. 1/8
The International Vaccine Institute (IVI) has announced the opening of a new Country and Project Office in Kenya, marking a significant step in the organization's efforts to advance vaccine research and development in Africa. This office will serve as the headquarters for IVI's Advancing Vaccine End-to-End Capabilities (AVEC) initiative in Africa and will collaborate closely with local partners, including the Kenya BioVax Institute.
The AVEC Africa project aims to accelerate the development and manufacturing of vaccines in the region through end-to-end research and development projects. By fostering public-private partnerships and providing hands-on training, AVEC Africa seeks to strengthen the vaccine ecosystem in Africa and ensure sustainable vaccine manufacturing.
Dr. Jerome Kim, Director General of IVI, expressed his excitement about the launch of AVEC Africa and the establishment of the Country and Project Office in Kenya. He emphasized the importance of collaboration with the Kenyan government and local research institutions to achieve the goals of the initiative.
The launch of AVEC Africa was announced during an event co-hosted by IVI, the Government of Kenya, and the Africa CDC. The initiative has received strong political support from African leaders, including H.E. Dr. William Ruto, President of Kenya.
The new Country and Project Office in Kenya will oversee the implementation of the AVEC Africa initiative and manage its project portfolio. This expansion reflects IVI's commitment to addressing global health challenges and building resilient vaccine ecosystems.
"With the strong support of the Kenyan Government, through @MOH_Kenya and its agencies including @BioVaxInstitute and @KEMRI_Kenya, AVEC Africa imagines a whole-of-continent approach aligned with the vaccine manufacturing goals of @AfricaCDC and @_AfricanUnion"
"The setting up of the IVI AVEC Project Office in Kenya will go a long way in supporting the establishment of local vaccine manufacturing capabilities here at BioVax."
Rwanda is delighted to host @IVIHeadquarters Africa Regional Office here in Kigali. This is an important milestone towards a fully resilient Africa through vaccine discovery and Research & Development.
Announcement: IVI to open Africa Regional Office in Rwanda! 🇷🇼
Through this office, we will foster partnerships with stakeholders across the continent for vaccine R&D and training to support sustainable #africanvaccinemanufacturing
"The @IVIHeadquarters Africa Regional Office has found an excellent home in Kigali and we are proud to have the support of @RwandaHealth and @Uni_Rwanda, which will be a critical technical partner."
"Hosting the IVI Africa Regional Office is yet another milestone towards a resilient Africa with regard to potential public health emergencies and we are honored to serve as its host."
“The @WHO licensure of SK bioscience’s TCV represents the successful conclusion of a global public-private partnership to bring to market a novel vaccine crucial to global public health.” #takeontyphoid
💬 Dr. Sushant Sahastrabuddhe, Director of IVI’s Typhoid Program
“In collaboration with #skbioscience and other partners, IVI will continue endeavors to make this vaccine accessible to people who need them the most.”
New in @TheLancetInfDis: A systematic review, meta-analysis, and modelling study for #chikungunya seroprevalence, force of infection, and prevalence of related chronic disability in endemic and epidemic settings.
Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study
Thank you Dr. @Vbiruta@RwandaMFA for a great meeting on the sidelines of the 37th @_AfricanUnion Summit! We appreciate the opportunity to introduce the Advancing Vaccine End-to-end Capabilities in Africa (AVEC Africa) initiative to build up an integrated vaccine ecosystem.
Thank you Your Excellency Firehiwot Abebe, State Minister @FMoHealth, for meeting with the @IVIHeadquarters team following #37ausummit. With our successful history of collaboration with partners like @AHRI_ETH, we are excited to further pursue joint R&D and capacity-building.
🚨 The deadline for applications is fast approaching!
Apply now to join the Spring 2024 cohort of the Introductory Course for Biologics Development and Manufacturing organized by the Global Training Hub for Biomanufacturing (#gth_b) @MOHW_eng@WHO
🔔 The application period is now OPEN for the 2024 Introductory Course for Biologics Development and Manufacturing organized by the Global Training Hub for Biomanufacturing (#gth_b) @MOHW_eng@WHO
We are incredibly grateful for this opportunity to advocate for end-to-end vaccine R&D projects as the pathway to an integrated and sustainable vaccine ecosystem in Africa. Thank you to our collaborators @BioVaxInstitute@AfricaCDC@_AfricanUnion and our esteemed speakers!
H.E. the President of the Republic of Kenya @WilliamsRuto co-hosted a high-level breakfast meeting with the International Vaccine Institute and the Africa CDC on ‘Sustainable Vaccine Manufacturing through End-to-End Vaccine Research & Development Projects in Africa’ (Cont')
International Vaccine Institute (IVI) reposted
AU Health,Humanitarian Affairs&Social Development@AU_HHS
High level working breakfast on “Sustainable vaccine manufacturing thru end-to-end vaccine research&development projects in Africa,” on t/margins of the 3️⃣7️⃣ Ordinary Session of the Assembly of @_AfricanUnion co-hosted by 🇰🇪, International Vaccine Institute & @AfricaCDC. 📍Hyatt
We are incredibly grateful for the support of H.E. Dr. @WilliamsRuto, Heads of State, experts from the #africanvaccinemanufacturing industry, and health agencies to champion partnerships that will help realize a self-sufficient and sustainable vaccine ecosystem on the continent.
Co-hosted a meeting on vaccine manufacturing in Africa with the International Vaccine Institute (IVI) in Addis Ababa, Ethiopia.
President Mohamed al-Menfi (Libya) was present. Others were Ahmed Hachani (Prime Minister, Tunisia), IVI Director-General Jerome Kim, Africa CDC Director-General Jean Kaseya, among others.
Happy Year of the Blue Dragon! For our friends and partners in Korea and around the world celebrating: we wish you a very happy and healthy #lunarnewyear #새해복많이받으세요 🌑
🎉This year we are celebrating TDR’s 50th anniversary!
Building on our rich history, we have developed a new Strategy for 2024-2029. Join us as we democratize research to reduce the burden of infectious diseases of poverty: tdr.who.int/publications/i/item/9789240074781
Today is #worldntdday, a global call to unite and act to address the inequalities that drive neglected tropical diseases, a group of 20 conditions affecting over 1️⃣ billion people around the world
🔔 The application period is now OPEN for the 2024 Introductory Course for Biologics Development and Manufacturing organized by the Global Training Hub for Biomanufacturing (#gth_b) @MOHW_eng@WHO
We strongly encourage applications from technicians, engineers, scientists, and managers with up to 6 years of experience in bioproduction currently employed by an organization registered in a low- or middle-income country.
As 2⃣0⃣2⃣3⃣ winds down to a close, we reflect on a year of progress and accomplishments made possible by the continuous support and collaboration from our partners around the world.
📢 IVI and EuBiologics are thrilled to announce that Euvichol-S, a simplified formulation of Euvichol-Plus® oral cholera vaccine, prequalified by @WHO, has been licensed for export by the Korean Ministry of Food and Drug Safety.
This licensure of Euvichol-S follows a comprehensive phase 3 clinical trial conducted by IVI and paves the way for a potential solution to the critical shortage of OCV worldwide.
🏆 Congratulations to #flemingfund regional grantee @IVIHeadquarters on leading @CIDJournal supplement 'Capturing Data on Antimicrobial Resistance Patterns & Trends in Use in Regions of Asia' - including 14 articles from #captura consortium on strengthening AMR data surveillance.
The #captura project, led by IVI and supported by @FlemingFund, unearthed & analyzed historical #amr data from 72 laboratories across 7 Asian countries to provide policy recommendations on strengthening national surveillance programs and aligning with international efforts
The #captura project, led by IVI and supported by @FlemingFund, unearthed & analyzed historical #amr data from 72 laboratories across 7 Asian countries to provide policy recommendations on strengthening national surveillance programs and aligning with international efforts
Dr. Gaurav Pandey, Head of Vaccine Process Development, represented IVI at the 2023 Health Cooperation Forum in the Indo-Pacific Region co-hosted by @MOFAkr_eng@StateDept@dfat to discuss vaccine and healthcare cooperation between 🇰🇷🇦🇺🇺🇸 and @ASEAN in the post-COVID era
Thank you for the opportunity to introduce our work to build resilient vaccine ecosystems in the Indo-Pacific and beyond alongside an expert line-up of vaccine and public health leaders including Dep Dir Dr. Sunate Cheunkitmongkol of @NVITH_Official, a long-term partner of IVI 🤝
The 4th and final session of #chikglobalmeeting is all about vaccine access: what are the perspectives on policy, financing, and demand for #chikvaccines?
"Meetings like this that bring all the stakeholders together to discuss critical public health issues are important. We have industry representation, health providers, governments of countries that are impacted by chikungunya and global regulators"
"Chikungunya is a global threat and really needs attention.
There is a requirement to characterize the disease—which can separate it from dengue—and for better surveillance so that we know the actual disease burden."
"Learning from others is very important to understand an issue...I hope this meeting helps us face the problem of chikungunya and think about solutions for the close future"
🗨️ Dr Elsa Marina Rojas, Centro de Atención y Diagnóstico de Enfermedades Infecciosas
“The reason we are all here together is very clear: we are at the front of the fight against chikungunya and other arboviruses, and vaccines are always the means to help us control and prevent these diseases”
2M+ cases of #chikungunya have been reported worldwide since 2005 🦟
Safe, effective, widely available vaccines can't wait. IVI & @InstitutoGorgas are organizing the first global meeting to advocate for a global #chikvaccines agenda
"It is very important to invest in research and development for neglected tropical diseases—especially since there are a lot of populations living in these tropical areas.
We have to control the preventable diseases with vaccines."
We kicked off the #chikglobalmeeting with a press briefing, gathering health and science journalists in Panama to shed light on #chikungunya and its growing threat to global health 🦟🌎
Coming soon 🔔 Chikungunya Virus: Recent Outbreaks, Vaccine Development, and the Way Forward
The first #chikungunya global meeting, organized by IVI & @InstitutoGorgas to map a comprehensive landscape of the problem of #chikv and its solutions 🦟💉
📢 CEPI, @IVIHeadquarters and @mrcunitgambia today announced the launch of the Research Preparedness Program West Africa (RPPWA), a new partnership to bolster clinical research capacity in West Africa to combat regional viral threats.
“IVI has been actively engaging with partners across West Africa for decades, jointly conducting multi-country disease surveillance and vaccine effectiveness studies in the region"
🗨️ @drflorianmarks, Deputy Director General of Epidemiology, Public Health, Impact at IVI
"Our activities in the region will extend beyond supporting current and future Lassa fever vaccine studies, encompassing systems- and infrastructure-strengthening across West African study sites"
🗨️ Dr Birkneh Tadesse, Head of Real-World Evidence, IVI
IVI's Acting Deputy Director General of Clinical, Assessment, Regulatory & Evaluation @SushantSahastr1 speaks to @VaccineInsights about lessons learned from the COVID-19 experience in supporting the clinical trial ecosystem in resource-limited settings
Developing new and improved vaccines while increasing access to existing ones would protect even more people and communities from vaccine-preventable diseases and reduce the need for antimicrobials.
According to a Global Research on Antimicrobial Resistance (GRAM) report, AMR was directly responsible for an estimated 1.27 million deaths worldwide in 2019.
That makes #amr a significant global health concern, sometimes referred to as a "silent pandemic."
AVA is conceived as a pan-African grassroots initiative built from the ground up with training programs, locally managed projects and public-private partnerships designed to make impact
The State Parties of IVI call for global solidarity in preparing against emerging and endemic infectious diseases with a commitment to strengthening vaccine research, development, manufacturing, and training at national, regional, and global levels.
At #worldbiosummit 2023 co-hosted by @mohw_eng and @who, IVI was honored with a plaque of appreciation from the Ministry of Health & Welfare of the Republic of Korea for our contributions to the success of the Global Training Hub for Biomanufacturing for the past two years 🏆
IVI and @CEPIvaccines co-hosted the "Vaccine Session" of World Bio Summit 2023, focusing on the implementation of CEPI's 100 Days Mission to respond swiftly and effectively to infectious diseases of epidemic and pandemic potential ⤵️
Today is World Children’s Day, promoting childrens' rights and improvements in childrens' welfare worldwide. In this op-ed in The Korea Herald, I urge governments and the int'l community to pay immediate attention to falling vaccine confidence. www.koreaherald.com/view.php?ud=20231119000172
The HKJC Global Health Institute aims to advance vaccine R&D and pandemic readiness, bringing the latest translational vaccine technology to Hong Kong while offering a robust training and education program.
"The establishment of the HKJC Global Health Institute brings together the best of all our organizations, an exemplar of positive cooperation between research, academia, and philanthropy"
IVI officially announced the launch of SAVAC 2.0, the next chapter of the Strep A Vaccine Global Consortium, gathering the #strepa vaccine research community, funders, and others working toward the development and availability of safe, effective, and affordable vaccines 💜💉
We officially announced SAVAC 2.0 ahead of #rhdcongress, gathering global stakeholders working to develop safe, effective, and affordable #strepavaccines Left untreated in childhood, Strep A infections can lead to rheumatic heart disease, causing heart failure later in life.
@biofarmaID's Bio-TCV® typhoid conjugate vaccine (TCV) was licensed in Indonesia following marketing approval from @BPOM_RI, the national regulatory authority 🇮🇩
"With emerging evidence that climate change and the increasing rise of #amr are impacting the prevalence and severity of typhoid fever, prevention through vaccination is a key measure for typhoid control"
IVI is working hard for sustainable vaccine manufacturing in Africa through support of end-to-end vaccine development activities through an Africa-based, African led initiative -- the African Vaccine Alliance.
Today, we concluded the 22nd Scientific Advisory Group meeting, an annual showcase of active IVI projects across all of our research teams, from laboratory science to vaccine clinical development, epidemiology, and vaccine effectiveness. #ivisag
Scientific presentations and posters ranged in topic from:
🔎 Development of a microneedle array patch-based vaccine 🔎 COVID-19 household transmission 🔎 Global chikungunya vaccine clinical development 🔎 HPV vaccine single-dose impact 🔎 AMR surveillance in Asia
We're grateful to Dr. Christian Mandl for chairing this meeting for the past 6 years and to SAG members for asking guiding questions and providing invaluable insights and encouragement to our scientists.
Congratulations to all for 2 rigorous days of presentations and discussion!
International Vaccine Institute (IVI) reposted
Secretaría de Prensa de la Presidencia@SecPrensaSV
IVI, in partnership with @KEMRI_Wellcome and K-Bio CMO, kickstarted the 2023 Hands-on Training for Upstream Process in Vaccine Manufacturing with an opening ceremony @IVIHeadquarters 🎊
For our annual Foundation Day, we put teamwork on full display through our signature IVI Mini Olympics
Whether we spend our days in a lab, at one of our 40+ field sites around the world, or at HQ, we are One IVI working toward a common mission #vaccinesforglobalhealth
Commemorating our 26th anniversary, we honored Dr. Richard Mahoney with the IVI Founders Medal🏅 for his remarkable contributions to the founding of IVI
Members of the Ambassadors’ Spouses Association of Seoul (ASAS) visited IVI HQ to learn more about our work and lessons from the field, where vaccine science meets community health.
This week at HQ, we kicked off the didactic component of the KOR-IDB Biomanufacturing Training with bio-production personnel from Latin American countries.
The curriculum covers the initial stages of vaccine R&D to the final stages of production and manufacturing. Learn more ⤵️
International Vaccine Institute (IVI) reposted
Instituto de Salud Carlos III (ISCIII)@SaludISCIII
Nuestro subdirector de Programas Internacionales de Investigación y Relaciones Institucionales @druiziruela ha representado a España y al #isciii en la reunión del Consejo Global del Instituto Internacional de Vacunas, celebrada en Corea del Sur.
International Vaccine Institute (IVI) reposted
Embassy of Rwanda in Korea, Cambodia and Laos@RwandainKorea
Inaugural Session of the IVI Global Council. #rwanda is represented by @RBCRwanda Director General, Prof. Dr. Claude M. Muvunyi. @IVIHeadquarters Director General, Dr. Jerome Kim (@drjeromekim1) shared the IVI strategy and activities.
The #iviglobalcouncil is a platform for State Parties to discuss needs and solutions for vaccine research, development, and implementation as well as issues of vaccine equity, access, and capacity-building at global, regional, and national levels 🌍
Director General @drjeromekim1 said: "IVI remains committed to the development of vaccines against poverty-associated diseases and diseases of pandemic potential, providing training for vaccine R&D workers in LMICs, and laying the groundwork for an African Vaccine Alliance"
At the #gtfcc and listening to countries describing the successes and challenges of implementing cholera control measures in this global crisis of cholera outbreaks. Champions all!
📽️The #gtfcc OCV Working Group visited #eubiologics 🇰🇷 to witness #bts of the life-saving oral #cholera vaccine production, as calls to increase OCV supply grows.🏭Special thanks to CEO Dr. Yeongok Baik + team and @IVIHeadquarters for hosting us. Glimpse of #gtfccinseoul below ⏬
On the 10th anniversary of the creation of the #cholera vaccine stockpile, we were very happy to hold the Global Task Force on Cholera Control's annual #ocv Working Group meeting at IVI HQ 🎊
🌎 Exciting times ahead! The #gtfcc Oral Cholera Vaccination (OCV) Working Group meeting has kicked off in #seoul 🇰🇷 as we celebrate a decade of the #cholera stockpile! Follow us for updates and insights as we go live from @IVIHeadquarters ! #gtfccinseoul
The annual @SecGTFCC#ocv meeting gathered stakeholders directly impacted by #cholera as well as health officials, researchers, and global health funders coming together to align on sustainable and collaborative solutions to #endcholera
📢We are super thrilled to announce an interesting public lecture on "Vaccine Development & Medicine Financing" with speakers from @IVIHeadquarters. Join us #urcmhs for an enlightening session!
Great discussion between @WHO and the International Vaccine Institute @IVIHeadquarters about the potential for local #vaccine manufacturing in #africa!
BREAKING NEWS The 2023 #nobelprize in Physiology or Medicine has been awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
IVI is pleased to work together with new and long-time collaborators in Ghana to scale up sustainable vaccine manufacturing capacities domestically and across the African continent 🤝🇬🇭
Through the generous core contributions to IVI from the governments of India, the Philippines, and Thailand, we were able to award scholarships to participants from @ICMRDELHI@NVITH_Official and @DOHgovph to attend #ivc2023 in Seoul.
🎖️ @NobelPrize Laureate in Chemistry, Prof Joachim Frank @Columbia, visited IVI with Prof Bhanu Jena @waynemedicine to deliver a special seminar on their research in biochemistry and cell biology
Thank you to both professors for discussing their seminal work with our scientists!
International Vaccine Institute (IVI) reposted
Int. Centre for Antimicrobial Resistance Solutions@ICARS_global
💡 Dr Jyoti Joshi, ICARS AMR Advisor, recently shared insights at the 22nd @IVIHeadquarters´ Vaccinology Course, delving into vaccines' potential in pandemic prevention, climate change, and their crucial role in addressing #amr across the #onehealth Spectrum.
We're grateful to Ambassador @StewartNyakotyo of Zimbabwe to Japan and Korea and Counselor Lameckh Bodo Matsiwe @zimtokyo2023 for visiting IVI during their official visit to Korea 🇿🇼
A round of applause for the 90 trainees who completed 5 intensive days of #lessonsforvaccinology and a big thank you to the lecturers and speakers for their insights and guidance 👏
And for our 5th and final day of #ivc2023, we are considering vaccines in different contexts: climate change 🦟 health economics 📈 the global burden and rise of antimicrobial resistance 💊
We were happy to host @cjcastillop, General Director of Planning and Evaluation @AMEXCID, Mexican Ambassador to Korea @carlospenafiels and Mr. Diego Dominguez, Head of Economic, Trade and Cooperation Affairs @EmbaMexCor for a productive meeting at IVI HQ 🤝🇲🇽
Today's #lessonsforvaccinology focused on vaccine introduction and delivery with lectures on real-world experiences from a mass typhoid conjugate vaccine campaign in Fiji, new platforms like the microneedle array patch, maternal immunization, and more! #ivc2023
On Day 4 of #ivc2023, Vaccinology Fellows present recent research 📊
Topics range from single-dose COVID-19 vaccination in Ethiopian health workers with prior SARS-CoV-2 infection, HPV vaccination in Tanzania, perception of clinical trials among participants in Nepal, and more!
IVI and Grid Biosciences sign a Memorandum of Understanding to pursue joint vaccine research as well as preclinical and clinical development, particularly for Epstein-Barr virus, which affects the majority of the world's population 🤝
At @karolinskainst in Stockholm, IVI Deputy Director General Dr. Anh Wartel chaired a panel discussion titled "Building vaccine manufacturing capacity" featuring:
🎙️ Dr. Martin Friede, @WHO 🎙️ Dr. Petro Terblanche, Afrigen 🎙️ Prof. William K. Ampofo, @AVMIAfrica
In addition to lectures, Day 3 of #ivc2023 features 2 panel discussions, the first case study, and the first round of posters presented by this year's Vaccinology Fellows
To continue with Vaccinology Essentials, Day 2 of #ivc2023 covers global health communications, vaccine effectiveness study, an overview of vaccine clinical development from first-in-human to licensure, and statistical methods for vaccine development
Dr. Pragya D Yadav, FAMS, FNAAS, FICMM, FIVS@hellopragya22
I am glad to see ICMR scientists in this training. Thank you so much for organizing this training for young scientists @IVIHeadquarters@icmr_niv@ICMRDELHI@IcmrNari@icmr_nims This will help for future vaccine research and pandemic preparedness
We are thrilled to wrap a successful Day 1 of #ivc2023!
From Seoul and Stockholm: thank you for the great questions and insights—we're looking forward to a week of new learnings, critical engagement, and collaboration #ivivaccinology#lessonsforvaccinology
We are thrilled to wrap a successful Day 1 of #ivc2023!
From Seoul and Stockholm: thank you for the great questions and insights—we're looking forward to a week of new learnings, critical engagement, and collaboration #ivivaccinology#lessonsforvaccinology
An early morning giving a talk on everything I know on immunology to students in @karolinskainst and Seoul for @IVIHeadquarters 22nd International Vaccinology Course. Looks like an interesting five days of talk on vaccines
We're live from Day 1 of the International Vaccinology Course!
Dr. Sushant Sahastrabuddhe, IVC Course Director, and @drjeromekim1, our Director General give opening remarks, welcoming everyone to Seoul and #ivc2023
Dr. Delese Darko, CEO of FDA received a joint delegation from DEK Vaccines Ltd, led by Dr Kofi Nsiah-Poku, Managing Director, and the International Vaccine Institute (IVI) led by Dr Jerome Kim, Director General.
We also had the opportunity to meet with VC/Prof. Rita Akosua Dickson and tour @KNUSTGH, a decade-long partner in typhoid burden research, and the KNUST-IVI Collaborating Center.
Many thanks to Prof. Ellis Owusu-Dabo, KNUST Pro-Vice Chancellor and PI of IVI's THECA program!
The Vice-Chancellor of Kwame Nkrumah University of Science and Technology, Prof. Mrs. Rita Akosua Dickson welcomed a 7-member delegation from the International Vaccine Institute (IVI), Seoul, Republic of Korea at the Council Chamber on August 29, 2023.
First, the IVI team met with Prof. Dorothy Yeboah-Manu and her colleagues @NMIMR_UG, followed by visits to the National Immunization Technical Advisory Group, National Vaccine Institute, @PATHtweets, and a meeting with @Dr_NsiahAsare, Presidential Advisor on Health 🤝
Noguchi Memorial Institute for Medical Research@NMIMR_UG
Dr. Jerome Hahn Kim, Director General of the International Vaccine Institute, @IVIHeadquarters together with some officials paid a working visit to @NMIMR_UG to explore opportunities for collaborations. (1/2)
An IVI delegation led by Director General @drjeromekim1 made a visit to Ghana, meeting with new and longtime partners across government, academia, and industry as we take steps to advance sustainable vaccine R&D and manufacturing in Ghana and beyond 🇬🇭
"It takes many people and disciplines to make a successful vaccine, and this course provides a stimulating and interactive introduction to modern #vaccinology" 🗨️ Prof Hazel Dockrell, @LSHTM
Through the partnership, IVI will provide technical services for @CEPIvaccines-funded projects, leveraging our expertise and capabilities to help accelerate vaccine development against pathogens with epidemic or pandemic potential 💉🌏
This week, IVI and the Madagascar Institute for Vaccine Research launched a vaccination campaign to protect children against #typhoid in Arivonimamo and Antananarivo-Atsimondrano, a key component of the Typhoid Conjugate Vaccine Introduction in Madagascar (TyMA) study 💉🇲🇬
The study aims to evaluate the real-world effectiveness of Vi-CRM197, a #typhoid conjugate vaccine pre-qualified by @WHO, in a high-burden setting as a step toward integrating the vaccine into routine vaccination programs in Madagascar.
"This campaign is the culmination of a 12-year research collaboration between IVI and MIVR to understand the burden of #typhoid fever in Madagascar...the campaign will not only protect nearly 60,000 children but help build an evidence-based case to register TCV in Madagascar."
A warm welcome to Ambassador Pablo Ernesto Scheiner Correa of Uruguay to the Republic of Korea! We look forward to working closely with Uruguay to advance global health through vaccine science 🇺🇾
During the @MOHFiji#typhoid conjugate vaccine campaign, we spoke with nurses, teachers, community leaders and members, and government officials to hear what they think about the campaign
Lusio Tanoa, the headman of Makolei Village, made sure everyone in his community knew when the vaccine would be available and encouraged them to receive the #typhoid conjugate vaccine 💉
Unaisi got her #tcv during the first week of the @MOHFiji mass vaccination campaign and encourages everyone in the Northern Division to protect themselves against #typhoid!
It was an honor to welcome you Cabinet Secretary for Health @Nakhumicha_S@MOH_Kenya and your delegation to IVI!
We appreciate the Government of Kenya's support of our mission and our shared goal to boost regional #vaccine manufacturing on the African continent 🇰🇪
Led a delegation from 🇰🇪 to the International Vaccine Institute (IVI) in South Korea today. During the visit, I expressed my appreciation for the existing collaboration between Kenya and South Korea on Biovax, emphasizing the government's commitment to promoting preventive and promotive health measures. Kenya is steadily moving towards the manufacturing of vaccines.
💉 #fiji is currently conducting a #typhoid conjugate vaccine campaign in the Northern Division. Shivanjali, a sixth grader, says she is happy she got the vaccine “because I won’t get the infection.” #vaccineswork to #takeontyphoid
A mass vaccination campaign is currently underway in Fiji to project communities against #typhoid 🇫🇯
For 8 weeks, teams of @MOHFiji public health workers are traveling across the Northern Division with the aim of reaching everyone ages 9 months to 65 years
The goal is to reach at least 80% vaccination coverage in an effort to eliminate typhoid in the Northern Division, which records reoccurring outbreaks of the disease
New #amr research in @GlobalHealthBMJ makes a case for increasing coverage of existing vaccines and developing new vaccines as an effectives means of reducing the spread of antimicrobial resistance ⤵️
A preventive vaccination campaign using #typhoid conjugate vaccine is underway in Fiji!
Learn more about the @TyFiveProject and our joined efforts with @MOHFiji to protect nearly 135,000 people against typhoid and understand the typhoid epidemiology in the Northern Division ⤵️
In conjunction with the typhoid conjugate vaccine campaign in #fiji, @IVIHeadquarters is also helping to strengthen the #typhoid surveillance system to better understand typhoid burden in the northern division
Hon. Dr. Ratu Atonio Rabici Lalabalavu, Minister @MOHFiji said:
"I am hopeful the impact of this typhoid vaccination campaign will be far-reaching, not only reducing morbidity and mortality but also having economic and social benefits for the North and the nation as a whole"
"Vaccines are a critical tool for #typhoid control, and we anticipate that this preventive campaign will have a significant impact in relieving the typhoid burden in the Northern Division"
Congratulations to the 180+ trainees representing over 40 countries who finished the 2-week #gthb course on #vaccine development, production, regulatory process, and more!
Their combined expertise in public health, international business, and philanthropy will help guide IVI’s growth as both a pioneering research institute and a mission-driven international organization dedicated to vaccines and vaccination for global health www.ivi.int/ivi-welcomes-three-new-members-to-its-board-o…
IVI exchanged an MOU with Seoul National University to promote mutual cooperation in vaccine R&D to discover and enhance equitable global access to new and innovative vaccines 🤝
Many thanks to SNU President Honglim Ryu for signing the MOU as well as Vice President for Research Jae-young Kim and Dean of Research Affairs Byung-cheol Kang for joining us at the signing ceremony!
It was great to connect at IVI HQ around our shared goals, such as building regional cooperation for vaccine access and policy as well as resilient and sustainable immunization programs 🌎
The course features 5 days of lectures, interactive case studies, and site visits facilitated by a world-class faculty in addition to networking and feedback sessions
IVI at the #g20 Health Working Group meeting: Deputy Director General Dr. @t_wartel joins a panel discussion exploring major gaps in research for vaccine development ahead of the next global health emergency
It was great to welcome back to @IVIHeadquarters Ambassador @marciadonner4 from @BrazilEmbSeoul 🇧🇷 Thank you for your strong support of IVI and for championing partnerships with Brazilian vaccine R&D collaborators!
At @StateHouseKenya, Nairobi, had a conversation with the Director General of the International Vaccine Institute (IVI) Jerome H. Kim who is keen on collaboration with countries in the use of new and improved vaccines, research and technology transfer.
During our official visit to Senegal, we also had the opportunity to meet with H.E. Mame Baba Cissé, Secretary General of the Ministry of Foreign Affairs, to further discuss IVI’s future collaborations with the rapidly developing vaccine ecosystem in Senegal.
An @IVIHeadquarters delegation had the honor of making a courtesy call on H.E. President @Macky_Sall of Senegal We share a commitment to preventing infectious diseases and are working with partners like @PasteurDakar to build vaccine R&D and manufacturing capacity
Joined H.E President @WilliamsRuto in welcoming back to Kenya the Director General of the International Vaccine Institute (IVI) Jerome H. Kim @drjeromekim1. During the meeting, President Ruto said: "We are strategically supporting and providing incentives to strengthen the local manufacture of pharmaceuticals for effective, safe and affordable supply of medicines." @StateHouseKenya@MOH_Kenya@KEMRI_Kenya
In Nov 2022, in Seoul South Korea, H.E President @WilliamsRuto led Kenya's bid to join the International Vaccine Institute as a State Party. Today, I welcomed @drjeromekim1, the @IVIHeadquarters Director General to @MOH_Kenya Afya House, 🇰🇪.
This week, an IVI delegation led by Director General @drjeromekim1 made an official visit to Kenya, meeting with President @WilliamsRuto@StateHouseKenya who expressed his support for IVI and our shared efforts to build vaccine manufacturing capacity in Kenya and across Africa 🇰🇪
We are proud to announce a new partnership with @PasteurDakar!
Together, we'll work to grow IPD as a regional Center of Training Excellence for Biomanufacturing and collaborate on the clinical development and technology transfer of vaccines relevant to Africa 🌍
IVI and IPD share a goal of developing capacity in Senegal & across the continent at every stage of end-to-end vaccine manufacturing...building a sustainable biomanufacturing ecosystem in Africa that makes available safe, effective and affordable vaccines
Our partnership will greatly contribute to implementing our ambition to set up a regional training hub of excellence for the new African vaccine industry, creating a skilled and self-sufficient workforce in Senegal and other African countries
Cholera is a global emergency and it's time to fill the vaccine gap, IVI's Cholera Program Director Dr. Julia Lynch and Madeleine Zoeller argue in a new @AsiaBioSpectrum Opinion ⤵️
Today we were honored to host a team from @IVIHeadquarters who paid us a courtesy call. The team, led by their Director General @drjeromekim1, interacted with our researchers and learnt a lot about our research work at #kwtrp.
An IVI team visited @KEMRI_Wellcome to share our ongoing research across epidemiology, vaccine effectiveness, health policy and economics, clinical development, and more
Our Director General @drjeromekim1 also delivered a special seminar on Vaccines for Global Health 💉🌍
🔔Reminder: Applications for IVI Vaccinology Fellowships are due June 8, 2023
Apply for a fully funded opportunity to attend a 5-day training course building knowledge and practical skills related to the science of vaccines and how they are developed 👉 www.ivi.int/international-vaccinology-course-2023/
📢 Applications for IVI Vaccinology Fellowships are now OPEN
We highly encourage early-career researchers from low- and middle-income countries to apply for an opportunity to attend the 5-day course at its flagship location in Seoul
Many thanks to the Permanent Mission of France in Geneva and @MedsPatentPool for inviting me to join this panel on strengthening the entire vaccine R&D and manufacturing ecosystem in LMICs We need a sustainable and holistic approach to sufficiently prepare for the next pandemic
Panel one, including Dr Joe Phaahla @HealthZA, @drjeromekim1@IVIHeadquarters, Martin Friede @WHO & @maureenmurenga, is discussing the key elements needed to ensure the sustainability of regional manufacturing capacity that comes from the #mrna Technology Transfer Programme.
@GHTCoalition member @drjeromekim1 @IVIHeadquarters discusses need to look at entire ecosystem. We need R&D, workforce, clinical trials, regulatory capacity, & working with national and regional stakeholders to succeed in sustainable vaccine manufacturing
The Government of Kenya co-sponsored an event by @IVIHeadquarters on the sidelines of the #wha76 76th World Health Assembly on Empowering Biomanufacturing: how to equip countries for current and future infectious disease outbreaks
IVI organized an event on the sidelines of #wha76 with the Ministry of Health and Welfare of the Republic of Korea and sponsoring countries 🇧🇷🇬🇭🇰🇪🇷🇼🇸🇪🇹🇭
Empowering local biomanufacturing: How to equip countries for current and future infectious disease outbreaks
Minister of State @YvanButera shared 🇷🇼’s ongoing journey towards biomanufacturing in a #wha76 side event organized by @IVIHeadquarters themed “Empowering local biomanufacturing”.
IVI organized an event on the sidelines of #wha76 with the Ministry of Health and Welfare of the Republic of Korea and sponsoring countries 🇧🇷🇬🇭🇰🇪🇷🇼🇸🇪🇹🇭
Empowering local biomanufacturing: How to equip countries for current and future infectious disease outbreaks
Session 2 focused on the vision of the Global Training Hub for Biomanufacturing program and key takeaways from the first year of trainings and consultations
IVI and Nankai University establish the IVI Nankai Joint Vaccine Center in Tianjin, China 🎉
We aim to promote vaccine R&D and global health through science and technology, provide high-quality public goods to the world and train the next generation of vaccine professionals ⤵️
📢 Applications for IVI Vaccinology Fellowships are now OPEN
We highly encourage early-career researchers from low- and middle-income countries to apply for an opportunity to attend the 5-day course at its flagship location in Seoul
Build knowledge and practical skills related to the science of #vaccines and how they are developed while networking with a world-class faculty of experts and a truly international cohort of trainees 🌍
Last week, IVI held its annual face-to-face Board of Trustees meeting in Vienna, gathering our leadership from around the world and celebrating the opening of IVI's Austria Country Office 🇦🇹
Thank you to the Government of Austria for supporting this new office and @MFA_Austria for hosting a welcome reception at the Austrian Academy of Science!
The BOT meetings included a site visit to Polymun Scientific, developing and manufacturing biopharmaceuticals with private and public partners around the world 🧬
Technicians, engineers and managers working in bioproduction (vaccines, therapeutics, monoclonal antibodies) at a facility based in a low- or middle-income country
In 2022, this Intro Course for GxP trained more than 270 professionals from 34 countries
In addition to training courses, here's how IVI and the Korean Ministry of Health and Welfare @MOHW_eng are building up a global workforce for vaccine manufacturing ⤵️
What is DuoChol's potential impact on #globalhealth?
"With a need that exceeds the current supply of vaccine, the market requires additional producers as well as innovations to make vaccines that are lower cost, easier to use, and more efficacious"
IVI is conducting the DuoChol Phase I study in partnership with Dr. Jan Holmgren and scientists @goteborgsuni, Gotovax AB, and @valnevaSE who will produce the vaccine for the clinical studies
Thank you to @SingoeiAKorir, Principal Secretary for Foreign Affairs, Amb. Fred Matwanga, Director of Economic Affairs and Commercial Diplomacy, and delegation from @ForeignOfficeKE for visiting IVI HQ and reaffirming the Kenyan government’s support of IVI's mission and work 🇰🇪
Kenya's ratification of @IVIHeadquarters Treaty is premised on the understanding that prevention, detection & response to pandemics requires robust international cooperation & coordination. I visited IVI HQ. in Seoul & consulted with its CEO @drjeromekim1. @ForeignOfficeKE
We were also delighted to receive Mr. Kipkosgei Toroitich, Chargé d'Affaires a.i., and representatives from @KenyaSeoul as well as @MichaelLusiola, CEO of @BioVaxInstitute
Deputy Head of the UK Mission to Korea @gazweir@UKinKorea introduced Prof. Andrew Pollard and Prof. Sarah Gilbert and their illustrious careers in vaccine discovery and development, particularly in response to the COVID-19 pandemic
We proudly present the 2023 IVI-SK bioscience Park MahnHoon Award to co-recipients Prof. Sir Andrew Pollard and Prof. Dame Sarah Gilbert for their discovery and development of the Oxford/AZ vaccine, and dedication to vaccine equity 👏
Thank you @IVIHeadquarters and @FlemingFund for the partnership to address #amr nationally and globally. Investment in building systems and competency are critical for achieving #healthsecurity
We’re grateful to Minister @DechenwangmoM, @MoHBhutan for an inspiring meeting to discuss our @FlemingFund#captura work as well as potential areas of further collaboration across vaccines and AMR between IVI and Bhutan, a founding member of IVI! 🇧🇹
#captura@FlemingFund works with governments in South & SE Asia to expand the collection and availability of data on antimicrobial use, consumption and resistance 💊
We’re grateful to Minister @DechenwangmoM, @MoHBhutan for an inspiring meeting to discuss our @FlemingFund#captura work as well as potential areas of further collaboration across vaccines and AMR between IVI and Bhutan, a founding member of IVI! 🇧🇹
Our Director General @drjeromekim1 and an IVI team had the pleasure to meet with @rajesh_gokhale, Secretary of @DBTIndia, and Dr. Rajiv Bahl, Director General @ICMRDELHI, during an official visit to India to discuss further collaborative opportunities for vaccine R&D 🇮🇳
Thank you @dfg_public President Dr. Katja Becker and delegation for visiting IVI HQ 🇩🇪
We look forward to pursuing new opportunities together with DFG and German partners to advance vaccine R&D and capacity-building in the European region and beyond 🤝
#dfg President Katja Becker & delegation are visiting Seoul to advance new cooperation with Korean partners. 1st day was dedicated to meeting scientists @EwhaWomansUniv|Seoul National University & @IVIHeadquarters & representatives of research organizations at the German Embassy.
Como parte de mi agenda de trabajo, me reuní con la Sra. Youngmi Cho, jefa de Asuntos Globales y Comunicaciones del Instituto Internacional de las Vacunas (@IVIHeadquarters), organismo que promueve la investigación, el desarrollo y la difusión de conocimientos sobre las vacunas.
For 3 decades, @who has worked in all corners of the world to promote Health for All and the right to live a safe, productive, and fulfilling life regardless of who you are or where you live
Thank you for joining us in these meaningful discussions and for coming by to learn more about IVI and our Global Training Hub for Biomanufacturing program!
Today, we @UniIbadan@UniIbadan_COM Salmonella surveillance programs are reporting to a stakeholders on findings from our surveillance over the last circa 7 yrs & getting their input on ways forward. Surveill. partners includ @uchibadan_ & @IVIHeadquarters are here…/2
IVI and @Seegene_HQ partner for the Global HPV Burden Study 🤝
Using Seegene's innovative diagnostic tests, the study will determine the burden of HPV across 8 countries with high rates of cervical cancer but limited diagnostic capacity and access to prevention programs
“You can still influence decisions by practicing leadership from behind. Especially in the vaccine industry, you need to be humble because vaccine development can be a long and bumpy road"
Thanks to everyone who joined the Excursion to IVI on the final day of #gvirf
It was great to spend time face-to-face with our collaborators from around the world and to welcome graduate students from @unisiena pursuing a career in global health
Critical discussion and connections continue on Day 2 of #gvirf in Korea
As the co-organizer of the event, we're happy to see the vaccine and immunization community engaging in energizing panel sessions, workshops, and poster presentations 👏
The Global Vaccine and Immunization Research Forum #gvirf highlights the progress, challenges and opportunities in improving vaccines post COVID. @IVIHeadquarters Jerome Kim discusses the lessons learned and a framework for the future.
IVI's Director General @drjeromekim1 will deliver the keynote for #gvirf2023 Day 2: Translating pandemic R&D learnings into the broader global health agenda
We are thrilled to welcome Panama as a State Party of IVI 🇵🇦
Thank you to Health Minister @LPacoSucre for sharing encouraging words of support during today's ceremony and to Ambassador Athanasio Kosmas Sifaki for raising the flag of Panama at IVI HQ
“The decision by the Government of Panama to fully join IVI opens the opportunity to incorporate Panama's experience and expertise in our shared effort to rid the world of infectious diseases”
💬 George Bickerstaff, Chairperson of IVI Board of Trustees
“I am certain our renewed partnership will generate opportunities for further infectious disease research, vaccine clinical development, and related activities to advance public health in Panama, Latin America, and beyond”
IVI is heading to World Vaccine Congress Washington 2023!
Our Director General @drjeromekim1 is a keynote speaker and will join several panels on COVID-19 learnings and the need to invest in vaccine R&D for neglected diseases
Join us next Thursday (3/23) to hear from infectious disease experts and AMR researchers and policymakers on the value of vaccines in slowing the spread of #amr in LMICs
Join us in London for the 2nd International HEV Symposium on April 28-29
This symposium will bring together leading experts to present and discuss new data and research on #hev epidemiology, disease burden, diagnostics, and vaccines
Congratulations to our @ajpollard1 for being one of the recipients of the IVI-SK Bioscience Park MahnHoon Award for his outstanding contribution to vaccine development and global health.
We're grateful to the Philippines for supporting IVI's work to accelerate vaccines 🇵🇭
Thank you to Amb Ma. Theresa Dizon-de Vega @PHLinKorea for joining us on Vaccine Diplomacy Day where H.E. announced the contribution from the Philippine government
Thank you First Lady Madame Kim Keon Hee for becoming the 5th Honorary President of the Support Committee for IVI. Delighted to have the diplomatic community join us to recognize her inauguration. We look forward to her leadership & our combined efforts! news.sbs.co.kr/news/endPage.do?news_id=N1007108874
Good news in time for #internationalwomensday! A global study led by IVI & incl. KI researchers will investigate the #hpv-burden in girls and women, helping to inform intervention and R&D priorities. With funding from @gatesfoundation & @Utrikesdep.
"We hope to generate data that will inform effective strategies to prevent infection and ultimately introduce HPV vaccine into national programs, protecting the health of girls and women and reducing rates of cervical cancer"
It was great to meet Prof Sir Chris Whitty @CMO_England; Dame June Raine, Chief Executive @MHRAgovuk; Prof Isabel Oliver, Chief Scientific Officer @UKHSA
We had a great talk on aligning efforts btwn @IVIHeadquarters and UKHSA around pandemic preparedness and priority pathogens
Thank you Ambassador Federico Cuello @RDenCorea for your visit to IVI today!
We appreciate your strong support of IVI and our work to prevent infectious diseases through science. We look forward to working more closely with the Government of the Dominican Republic 🇩🇴
📣Announcing a call for applications for our new *Clinical Research Leadership* fellowship programme in collaboration with 14 training partners in Africa, Asia, Europe and the Americas: tdr.who.int/docs/librariesprovider10/calls-for-applicatio…
Thank you, President Kagame, for your strong support of Rwanda’s growing partnership with IVI 🇷🇼
We look forward to working with @RwandaGov and @_AfricanUnion to build vaccine manufacturing capacity in Africa and resilience against future pandemics
IVI Director General @drjeromekim1 sits down with @NationAfrica to discuss recent discussions with President Ruto and how IVI will work with organizations such as @BioVaxInstitute@KEMRI_Kenya to develop a sustainable and impactful vaccine R&D and manufacturing ecosystem in Kenya
What does Dr. So Jung An, Research Scientist at IVI, love about being a scientist?
"Designing new vaccine production and improving processes is a way of creating protocols rather than simply following existing ones. It is always exciting to try something new and creative!"
"Gender equality among national and global policymakers would have a powerful impact in driving the #globalhealth agenda and ensuring that all genders have equal access"
🗨️ Sunee Chuasuwan, Head of Clinical Operations and Trial Management at IVI
Today, UR sealed partnership with @IVIHeadquarters to enhance capacity-building thru short courses & Master’s programs in vaccines among other joint efforts. VC Dr @mdkayihura & @drjeromekim1, the #ivi DG represented the 2 institutions. #rwanda has been a member of IVI since 2022
Prof @CMuvunyi DG of @RBCRwanda today received the @IVIHeadquarters (IVI) board and management delegation led by George Bickerstaff the Chair of IVI Board of Trustees who toured the National Reference Lab and discussed on clinical trials and potential areas of collaboration.
Today, a delegation from The @IVIHeadquarters including George Bickerstaff, the Chair of IVI Board of Trustees, @drjeromekim1 , IVI Director General, and @t_wartel , IVI Europe Regional Director visited Rwanda FDA and discussed areas of collaboration.
This morning, the @IVIHeadquarters delegation visited the National Vaccine Warehouse and discussed vaccination programs, vaccine supply chain as well as vaccines research.
This afternoon, @nsanzimanasabin and @YvanButera held a meeting with a delegation from the International Vaccine Institute led by its Chair of Board of Trustees,George Bickerstaff and DG @drjeromekim1,& discussed potential areas of collaboration in the biomanufacturing ecosystem.
Thank you to President Kagame for supporting collaboration between IVI & @RwandaHealth
We greatly appreciate @UrugwiroVillage for welcoming IVI's Board Chair George Bickerstaff, Director General @drjeromekim1, Board Member Prof Leon Mutesa, and Europe Regional Director @t_wartel
Today, President Kagame met with George Bickerstaff, chair of @IVIHeadquarters Board of Trustees, @drjeromekim1, its Director General, and their delegation, for a discussion on vaccine research and development.
The Ty-Five consortium (IVI, @MOHFiji, @MCRI_for_kids, @UniMelb) aims to strengthen #typhoid surveillance in Fiji and launch a public health vaccination campaign in the Northern Division as a step toward typhoid elimination
Thank you to the Hon Minister for a great meeting!
Thank you also to the leaders of @KEMRI_Kenya@BioVaxInstitute@aphrc for a fantastic overview on Kenya’s R&D capabilities and aspirations for vaccine manufacturing. We are excited to explore opportunities for technology transfer and capacity-building with @IVIHeadquarters.
1/7: Kenya's bid to start manufacturing of human vaccines, biotherapeutics & diagnostics got a major boost on Monday following a meeting between the Cabinet Secretary for Health, Dr Nakhumicha S. Wafula & the International Vaccines Institute Director General, Dr Jerome Kim.
In Nov 2022, in Seoul South Korea, H.E President @WilliamsRuto led Kenya's bid to join the International Vaccine Institute as a State Party. Today, I welcomed @drjeromekim1, the @IVIHeadquarters Director General to @MOH_Kenya Afya House, 🇰🇪.
Watch this story of the people at the frontlines of vaccination during a campaign to protect nearly 100,000 people in Shashemene, Ethiopia using IVI's oral cholera vaccine 🇪🇹
Hallo Österreich! We are thrilled to announce that IVI has opened a Country Office in Austria 🇦🇹
IVI's new presence in Vienna will work closely with the local biomedical research network and mobilize collaborative vaccine R&D projects for global health 🌍
"I see four gaps in the global response to Covid-19: diagnostics, vaccine supply, vaccination, and leadership...The gap in pandemic leadership is at once the broadest and most intractable"
My First Opinion for @statnews covers the major gaps in global pandemic responses—diagnostics, manufacturing capacity, vaccination—while focusing on the most pressing: lack of leadership
The world needs leadership that can enforce equitable and timely distribution of vaccines
IVI and @Batavia_Bio entered a new partnership agreement to advance vaccines for #globalhealth, combining our network and collaborative experiences in low- and middle-income countries and Batavia's advanced production and quality control capabilities
"The reality is that the next pandemic will not wait to strike until LMICs are fully prepared, so we must build capabilities, infrastructure, and cooperation now"
Launched new offices and Collaborating Centers in Europe and Africa to engage new partners and pursue vaccine research, innovation, and capacity-building across continents 🌐
2022 marked IVI's 25th year as an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health
Our work is made possible by a global network of partners. Here's to the next 25 🌟
IVI’s @DrSeEunPark spoke on Korea-Africa partnership for Global Health Security Agenda and Pandemic Preparedness and Response at the 5th Seoul Dialogue on Africa hosted by the Korea-Africa Foundation and @MOFAkr_eng
We're grateful to the Northern Health Services of Fiji for awarding IVI's Typhoid in Fiji–Vaccination towards Elimination (Ty-FIVE) team with Best Partnership of the Year
Ty-FIVE aims to strengthen typhoid surveillance in Fiji and vaccinate the Northern Division against #typhoid
IVI wishes everyone a happy, healthy holiday season 🎁
We're grateful to our collaborators and supporters who make our work possible, and we're looking ahead to another year of making global health impact together 🌏
"This is high time that kids in India get [typhoid conjugate] vaccine as India has a huge burden of typhoid fever"
IVI Associate Director General @SushantSahastr1 explains how #typhoid conjugate vaccine works and advocates for its use in national immunization programs ⤵️
Public health experts point to the threat from another infectious disease for which a vaccine exists but is still not part of India’s free universal immunisation programme. scroll.in/article/1038541/
In this short film from @nature, IVI Director General @drjeromekim1 emphasizes regional vaccine manufacturing capacity as a key factor in closing equity gaps and preparing for the next inevitable pandemic
It was an enormous pleasure to welcome the Danish Minister for Health @Heunicke to IVI today and receive the exciting news that Denmark will contribute 4 million DKK to IVI this year 🇩🇰
Profs. Weissman and Karikó's innovations in mRNA vaccine technology were safe, effective, and practical for use, establishing a foundation for two #covid19 vaccines and potentially more life-saving vaccines and therapeutics in the future
Our Director General @drjeromekim1 answers top-of-mind questions from the @TEDTalks community and urges global cooperation in making sure everyone in the world has access to a safe and effective COVID-19 vaccine.